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Abstract 
 
 Atherosclerosis is both a chronic inflammatory disease and lipid deposition 
disorder characterized by accumulation of lipids, fibrous tissue, and inflammatory 
cells in the arterial wall. Thus, investigating the role of inflammation and the 
immune system in the progression of atherosclerosis may help in the development 
of novel therapeutics for atherosclerotic disease. Current atherosclerosis therapy 
is aimed at lipid targets and focused primarily on reducing plasma cholesterol 
levels. Clinical and experimental data support the critical role of inflammation in 
atherosclerosis and suggest that reducing inflammation even without affecting lipid 
levels may reduce the event rate of cardiovascular disease. Yet, no pure anti-
inflammatory drugs are used to treat patients with atherosclerotic diseases. 
Recently, the Canakinumab Anti-inflammatory Thrombosis Outcomes Study 
(CANTOS) provided evidence that targeting inflammation by inhibiting IL1-β 
reduced the rate of cardiovascular events, providing support for the inflammation 
hypothesis of atherosclerosis. In this study, we aim to test the inflammation 
hypothesis using various immunomodulatory approaches. First, we measured the 
expression of inflammation markers in human atherosclerotic carotid arteries. We 
demonstrated that markers of inflammation were significantly increased in plaques 
compared to normal media and those markers positively correlate with miR155, a 
pro-inflammatory microRNA. We observed that miR155 was up-regulated in the 
vi 
calcified media occurred concomitant with osteogenic genes; and cell culture and 
mouse studies further suggested a causal role of miR155 in vascular calcification. 
In the second study we observed that bone marrow tristetraprolin (TTP) deficiency 
in LDLR−/− mice significantly increased systemic inflammation. Unexpectedly, 
serum lipid levels and hepatic steatosis were dramatically reduced, likely due to 
reduced lipid production in the liver by downregulating SREBF1. Increased 
inflammation and reduced serum lipid offset each other and result in unchanged 
atherosclerosis. This model may provide an opportunity to examine the 
relationship between inflammation and lipoprotein metabolism. We also 
investigated the effect of macrophage-specific GP96 deficiency on atherosclerosis 
to determine the role of toll like receptors (TLRs) during atherogenesis. Our results 
show that macrophage-specific GP96 deficiency did not change inflammatory 
status, serum lipid, and atherosclerosis in LDLR−/− mice. Sparstolonin (SsnB), a 
selective TLR2/TLR4 inhibitor, is known to have anti-inflammatory effects. In this 
study, we injected mice with super-low dose LPS or LPS plus SsnB. Super-low 
dose LPS increased serum chemo-attractants, while SsnB reduced these 
chemokines. However, super-low dose LPS and SsnB administration did not affect 
atherosclerotic lesions. Atherosclerosis is a complex, multifactorial process, and 
the interaction between inflammation and atherogenesis is complicated as 
indicated by our results. Since CANTOS shows that targeting inflammation 
reduced the rate of cardiovascular events, it opens the field to further examine the 
inflammation hypothesis of atherosclerosis and to explore novel therapeutic 
avenues by targeting inflammation.
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Chapter I  
Introduction 
1.1 Atherosclerotic cardiovascular diseases 
Cardiovascular diseases (CVDs), including myocardial infarction (heart 
attack) and angina pectoris (chest pain), represent the leading causes of mortality 
and long-term morbidity worldwide1. The incidence of CVDs continues to rise and 
is projected to remain as the number one cause of death globally by 20202. 
Atherosclerosis is by far the main underlying pathological process of coronary 
artery disease, carotid artery disease, and peripheral arterial disease — which are 
among the most prevalent CVDs3. 
The term ‘atherosclerosis’ comes from Greek word "athero" meaning gruel, 
and sclerosis means hard — which is hardening with loss of elasticity leading to 
narrowing of the arteries. Atherosclerosis is both a lipid deposition disorder and a 
chronic inflammatory disease, characterized by formation of atherosclerotic plaque 
in the arterial wall4,5. It mainly affects medium-sized and large arteries such as: the 
aorta, coronary arteries, carotid arteries, and renal arteries, in focal areas — 
particularly regions in which laminar flow is disturbed (e.g. arterial branch points 
and bifurcations)6,7. The disease begins early in life and goes undetected until 
thrombotic complications, such as acute coronary syndromes and stroke occur8. 
There are numerous genetic and environmental risk factors associated with 
atherosclerotic diseases. Most of the environmental risk factors are modifiable and
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reversible, whereas the genetic factors are not. Clinically significant lesions are 
usually associated with hypercholesterolemia, smoking, diabetes mellitus, 
hypertension, obesity, physical inactivity, family history, and high-fat diet (HFD)8-9. 
It has been shown that hypercholesterolemia alone is sufficient to drive the 
development of atherosclerosis. However, the presence of other risk factors 
appears to accelerate disease progression, driven by the atherogenic lipoproteins 
(i.e. low-density lipoprotein; LDL)10.  
1.2 Structure of blood vessel wall  
The normal wall of blood vessels consists of endothelial cells, vascular 
smooth muscle cells (VSMCs), and extracellular matrix (ECM) arranged in three 
different layers (from innermost to the outermost): the intima, media, and 
adventitia11. The tunica intima is composed of a single monolayer of simple 
squamous cells known as endothelial cells. It lies on the internal elastic lamina, a 
layer of elastic fibers, which defines the outermost boundary of the intimal space 
and separates the intima from the media. The endothelial layer represents the 
interface between circulating blood flow and the vascular wall — providing a 
smooth lining for blood vessels12. The endothelial cells have a significant role in 
regulation of vascular permeability, regulation of immune responses, modulation 
of blood flow and vascular resistance, platelet aggregation, and thrombosis 
prevention. These are achieved by releasing anti-platelet, anti-coagulant, anti-
thrombogenic, and fibrinolytic factors in addition to the production of the potent 
vasodilator nitric oxide (NO)13. Besides the vasodilators, endothelial cells also 
produce some vasoconstrictor molecules, such as endothelin and angiotensin-II, 
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which can also promote proliferation of smooth muscle cells and thereby contribute 
to plaque formation14,15. Therefore, the ability of the endothelial cell layer to repair 
itself and to maintain functional and structural integrity, is key to the prevention of 
atherosclerosis16,17.   
The middle layer of the arterial wall is the tunica media, which is composed 
primarily of VSMCs surrounded by a network of ECM proteins including elastic 
fibers, collagen, and proteoglycans. This layer provides strength and elasticity to 
the blood vessels so they can stretch or expand without tearing18. The outermost 
layer is the tunica adventitia, which is primarily composed of irregularly arranged 
collagen bundles, scattered fibroblasts, a few elastic fibers, and small blood 
vessels called vasa vasorum. Vasa vasorum provides oxygen and nutrients to 
outer layers of the vascular wall. The elastic collagen fibers allow arteries to stretch 
to prevent over-expansion due to higher pressures in these blood vessels19-20. 
Understanding the structure and function relationship of each layer in the arterial 
wall provides insight into the pathophysiology of arterial wall diseases, such as 
atherosclerosis, and allows for better predictions for prevention and treatment 
strategies. 
1.3 Pathogenesis of atherosclerosis 
Atherosclerosis is a complex and multifactorial disease characterized by 
systemic and vascular wall inflammation and activation of immune pathways, 
dyslipidemia, endothelial dysfunction, foam cell formation, VSMC activation, 
platelet activation, and thrombosis21,22. A number of hypotheses have been 
proposed to describe the pathogenesis of atherosclerosis including the: response 
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to injury hypothesis23, response to retention hypothesis24, LDL-oxidation 
hypothesis25, lipid hypothesis26, and inflammation hypothesis27. A better 
understanding of the pathogenesis of atherosclerosis will aid in formulating 
preventive and therapeutic strategies to reduce the mortality rate of cardiovascular 
events. 
1.3.1 Response to injury hypothesis 
The response to injury hypothesis suggests that atherosclerosis is initiated 
with injury-induced damage and dysfunction of the endothelial cells lining the 
intima. This damage caused by local disturbances of blood flow at branch points, 
along with systemic risk factors, perpetuates a series of events that culminate in 
the development of atherosclerotic plaque. Endothelial dysfunction is the initial 
step that allows entry and retention of cholesterol-containing LDL particles and 
inflammatory cells (i.e. monocytes, T lymphocytes) into the sub-endothelial 
spaces, altering normal homeostasis28,29,30. Under normal homeostatic 
conditions, the white blood cells do not adhere to the endothelial cells lining the 
intima. However, under atherogenic conditions, the damaged endothelial cells 
express surface adhesion molecules such as vascular adhesion molecule-1 
(VCAM-1), leading to adhesion of circulating blood monocytes to the endothelial 
surfaces. Those monocytes ultimately migrate to the sub-endothelial space. When 
acting together with imbalance between vasoconstriction and vasodilation, these 
processes promote increased vascular permeability and platelet aggregation31. 
Furthermore, endothelial dysfunction is associated with decreased production of 
NO and increased cellular permeability to lipoproteins, each thought to be a key 
event in the development and progression of atherosclerosis32.   
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1.3.2 Response to retention hypothesis 
The response to retention hypothesis of atherosclerosis was initially 
proposed in 199524. Since then there has been several line of experimental 
evidence supporting this hypothesis. The response to retention hypothesis 
suggests that retention of cholesterol-rich, atherogenic lipoproteins within the sub-
endothelial space is the key initiating event in early atherosclerosis. Once retained, 
these lipoproteins increased susceptibility for modification/oxidation, and 
subsequently provoke the inflammatory response with increasing smooth muscle 
cell migration and phenotype switching as well as infiltration of inflammatory cells 
including macrophages24,30. 
1.3.3 LDL oxidation hypothesis 
The LDL oxidation hypothesis suggests that oxidative modification of 
lipoproteins, in particular LDL, within the arterial wall by reactive oxygen species 
(ROS) plays an important role in the pathogenesis of atherosclerosis25. 
Monocytes/macrophages express scavenger receptors that engulf oxidized oxLDL 
in an uncontrolled manner. In turn, uptake of oxLDL leads to accumulation of lipids 
and lipid-laden foam cells to form a fatty streaks — an early feature of 
atherosclerotic plaque formation25,33,34. Experimental data indicate that oxLDL 
within the arterial wall promotes the development of atherogenesis25. Additionally, 
inhibiting the oxidation of LDL could decrease or prevent atherosclerosis 
development. Previous studies have shown the efficacy of anti-oxidant treatment, 
such as probucol and vitamin E, which significantly reduced the severity of 
atherosclerosis in different atherogenic animal models. These studies supported 
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the oxidative modification hypothesis35. Furthermore, targeting some proteins 
involved in LDL oxidation and uptake of oxLDL (e.g. 12/15 lipoxygenase and 
scavenger receptors (SRA and SRB)) in various atherogenic murine models 
significantly attenuated the severity of atherosclerosis36–38.   
1.3.4 Lipid hypothesis 
The lipid hypothesis of atherosclerosis states that both lesion initiation and 
progression of atherosclerosis is primarily associated with hyperlipidemia26.  In the 
last decade, considerable advances in the understanding of cardiovascular risk 
factors have been established, and dyslipidemia has been shown as one of the 
most powerful risk factors. Controlling blood cholesterol is efficient at reducing 
cardiovascular risk and an important therapeutic decision, as the rate of CVDs 
were significantly reduced with decreased blood cholesterol39. The link between 
hyperlipidemia and atherosclerosis predominate, until the 1970s, based on strong 
experimental and clinical relationships between hypercholesterolemia and severity 
of atherosclerotic lesions. This was further supported by the fact that statins, lipid 
lowering agents, were able to significantly reduce atherosclerotic diseases40. 
The first description of an atherosclerotic lesion was recorded in 1908 when 
Alexander I. Ignatowski, an experimental pathologist, fed rabbits cholesterol for 17 
weeks followed by chow diet for 14 weeks. These rabbits developed pronounced 
aortic atherosclerosis41. In 1913, Anitschkow and colleagues proposed the 
fundamental role of cholesterol in the pathogenesis of atherosclerosis. They fed 
rabbits with a high-cholesterol diet and found that the blood cholesterol levels were 
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significantly increased, and indeed, within weeks those rabbits displayed vascular 
atherosclerotic lesions similar to those of human atherosclerosis42.  
In order to examine the lipid hypothesis of atherosclerosis induced by 
cholesterol, Clarkson and Newburgh (1926) fed rabbits a normal diet with various 
cholesterol doses for 47- 87 days. They discovered atherosclerosis in rabbits fed 
high cholesterol doses43. These observations strongly supported the theory that 
cholesterol was the main driving force in the development of atherosclerotic 
CVDs44.  
In the early stages of atherosclerosis, plasma LDL crosses the endothelial 
barrier and enters the intima. Once accumulated in the sub-endothelial arterial 
intima, LDL undergoes oxidative modification via the reactive oxygen species 
produced by macrophages and damaged endothelial cells, forming oxLDL34,22,45. 
oxLDL is a pivotal molecule representing the initial event in atherosclerotic lesion 
formation and progression by promoting inflammation, foam cell formation, and 
smooth muscle cell migration/proliferation46. oxLDL is also considered a potent 
chemo-attractant and strong pro-inflammatory stimulus, which recruits the 
circulating blood monocytes and T-cells to the sub-endothelial space47. Once 
retained in the intima, oxLDL activates endothelial cells and up-regulates the 
expression of adhesion molecules, such as VCAM-1 and intercellular adhesion 
molecule-1 (ICAM-1), and the secretion of chemokine/cytokines that contribute to 
the recruitment of circulating leukocytes48,49. oxLDL taken up by activated 
macrophages via scavenger receptors (SR-A, CD36, and Lox1) form lipid-laden 
foam cells — a hallmark of atherosclerosis. Activated macrophages and foam cells 
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secrete different pro-inflammatory cytokines and chemokines, which in turn attract 
more monocytes to the intima and potentiate the inflammatory response22,31,50. 
The role of plasma lipoproteins in atherosclerosis development has gained 
significant attention and has been demonstrated by randomized controlled trials. 
These studies revealed the rate of cardiovascular events were significantly 
reduced via inhibition of cholesterol biosynthesis using lipid lowering agents, 
mainly statins. Statins act by inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme A 
reductase (HMG-CoA Reductase); the rate limiting step in the cholesterol 
biosynthesis pathway40. The lipid hypothesis of atherosclerosis is now considered 
fact, supported by: 1) epidemiological studies that have shown a positive 
relationship between total cholesterol concentrations and the mortality rate of 
CVDs, and 2) the success of statin drug therapy in the past 40 years; statins 
significantly reduced atherosclerotic disease mortality through reducing plasma 
LDL levels39. 
1.3.5 Inflammation hypothesis 
In the last century, it was believed that atherosclerosis was merely a lipid 
storage disease, associated with hyperlipidemia and accumulation of cholesterol 
and fatty streaks in the arterial wall. Over the past two decades, studies 
demonstrated the complexity of atherosclerosis and the involvement of both the 
innate and adaptive immune systems by detecting different immune cells (e.g. 
monocytes, macrophages, dendritic cells (DCs) and T cells) associated with 
production of immune mediators within the arterial wall21. Presently, the role of 
inflammation in atherosclerosis is well recognized and accumulating evidence 
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indicates that inflammation plays a key role in the pathophysiology of all stages of 
atherosclerosis from lesion initiation, through progression, and ultimately the 
thrombotic complications of atherosclerosis51.  
Inflammation in the arterial wall proceeds as a cascade, which begins with 
endothelial cell activation and expression of surface adhesion molecules such as 
VCAM-1, ICAM-1, selectins, and integrins that increase the adhesion of circulating 
blood monocytes to the endothelial cell layer lining the blood vessel 
wall52,53. Furthermore, the activated endothelial cells will secrete chemo-
attractants, such as monocyte chemoattractant protein-1 (MCP-1) also known as 
CCL2, that interact with chemokine receptors on blood monocytes and promote 
their recruitment and entry into sub-endothelial intimal space in a phenomenon 
known as diapedesis54,55,56. Once the blood monocytes migrate into the sub-
endothelial space, they activate and differentiate into macrophages, stimulated by 
macrophage colony stimulating factors (M-CSF)57–59. These activated 
macrophages exhibit high expression levels of surface recognition receptors called 
scavenger receptors (SR-A and CD36), which have the ability to engulf oxLDL and 
form lipid-laden foam cells within the sub-endothelial space. Further, these 
activated macrophages secrete inflammatory cytokines/chemokines including 
MCP-1, interleukin-1 (IL-1), and tumor necrosis factor-α (TNF-α) that increase 
adhesion and recruitment of monocytes into the lesion, potentiating the 
inflammatory response of atherosclerosis60,60,61. Over time, the lipid-laden foam 
cells coalesce and form a fatty streaks — characteristic of atherosclerosis and 
presenting at a very young age. Excessive lipid accumulation followed by 
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macrophage death results in enlargement of the atherosclerotic core, deposition 
of collagen fibers, and migration of smooth muscle cells from media into the intima. 
This ultimately leads to the irreversible formation of fibrous atherosclerotic plaques. 
Fibrous lesions usually have a fibrous cap composed of smooth muscle cells and 
ECM, which encloses a lipid-rich, necrotic core62. In addition to macrophages, 
atherosclerotic lesions contain other immune cells including dendritic cells, B 
lymphocytes, and T lymphocytes, notably CD4+ T cells and regulatory T cells, 
which regulate many innate immune pathways63–65.  
Vascular smooth muscle cells (VSMCs) play a fundamental role in 
atherosclerosis development66. The inflammatory mediators such as 
cytokines/chemokines and growth factors released by injured endothelial cells and 
inflammatory cells stimulate migration of VSMCs from the underlying media to the 
sub-endothelial space resulting in intimal area expansion. Additionally, VSMCs will 
switch from quiescent contractile phenotype to the proliferative, synthetic 
phenotype, characterized by excess production of ECM. This results in deposition 
of ECM proteins and formation of a fibrotic cap that covers the necrotic core and 
stabilizes/prevents plaque rupture66–69. Over time, these lesions become calcified 
and grow toward the adventitia. At a certain point, they begin to encroach to the 
lumen leading to narrowing of the blood vessels and the complications associated 
with atherosclerosis70.  
In the atherosclerotic lesion, monocytes can differentiate into two major 
types of macrophages: classically activated (M1) macrophages which promote 
inflammation and alternatively activated (M2) macrophages which stimulate 
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resolution of inflammation. An imbalance in the ratio of classically versus 
alternatively activated macrophages in advanced atherosclerosis leads to impaired 
resolution71,72. One important function of M2 macrophages is the clearance of 
apoptotic cells via a process called efferocytosis. Efferocytosis is a term refer to 
the engulfment or phagocytosis of antigen presenting cells such as macrophages 
and dendritic cells73. As macrophages engulf oxLDL in the arterial wall during early 
stages of atherosclerosis, these macrophages undergo apoptosis74. Apoptosis is 
a physiological, programmed, and energy-dependent cell death cascade. In early 
atherosclerosis, macrophage apoptosis is associated with reduced atherosclerosis 
progression. This is most likely due to effective efferocytosis by M2 
macrophages75,76. Efficient efferocytosis has been shown to induce anti-
inflammatory mediators, such as interleukin-10 (IL-10) and transforming growth 
factor-β (TGF-β)77.  As atherosclerosis progresses, efferocytosis is thought to 
become impaired. A lack of efferocytosis leads to secondary necrosis, where 
macrophages die and release their cellular contents including oxidized lipids and 
pro-inflammatory mediators. Secondary necrosis amplifies the inflammatory 
response and leads to the development of a necrotic core in the plaque78. 
Additionally, inflammatory cells and VSMCs in the atherosclerotic lesion release 
matrix metalloproteinases (MMPs), a family of proteolytic enzymes that degrade 
ECM, resulting in the thinning and degradation of the fibrous cap. This promotes 
plaque instability, leading to rupture of the atherosclerotic plaque mainly at the 
plaque shoulder region and the resultant clinical consequences, such as 
myocardial infarction and other thrombotic complications79–81.  
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Taken together, it is clear that inflammation indeed drives all phases of 
atherosclerosis. Therefore, several anti-inflammatory compounds have been 
examined as potential therapeutic strategies for the prevention of atherosclerotic 
complications using various atherosclerotic animal models82. Despite strong 
evidence arising from animal studies that lowering inflammation may be a 
promising strategy for decreasing atherosclerosis and its complications, results 
have yet to be recapitulated in humans. Various protein therapeutic strategies, 
such as anti-cytokine therapies, have received noticeable appreciation for clinical 
application because of their potential direct anti-inflammatory effects. However, 
these strategies will require extensive clinical evaluation and testing in randomized 
trials before implementation into practice. 
There are two large randomized controlled clinical trials testing the 
inflammation hypothesis of human atherosclerosis. These studies aim to evaluate 
whether inhibiting inflammation will decrease event rates and improve prognosis 
among patients with heart disease using anti-inflammatory agents. The 
Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) is 
evaluating whether interleukin-1β (IL-1β) inhibition by anti-human IL-1β 
monoclonal antibody (Canakinumab) can reduce the rates of myocardial infarction, 
stroke, and cardiovascular death among patients with a history of previous 
myocardial infarction and elevated levels of high-sensitivity C-reactive protein (hs-
CRP) — a clinical marker for chronic inflammatory conditions83. This study showed 
that the hs-CRP was reduced by 39% and reduced cardiovascular event rates by 
17%. This study validated the concept that targeting inflammation and 
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manipulating the immune system can reduce atherosclerosis without affecting lipid 
levels and provide a novel cytokine-based therapy for the secondary prevention of 
CVDs84. The second clinical trial that is still on-going is Cardiovascular 
Inflammation Reduction Trial (CIRT) which aims to elucidate whether treatment 
with low-dose  methotrexate (a common drug used in the treatment of autoimmune 
disorders such as rheumatoid arthritis and psoriasis arthritis) will reduce major 
vascular events among patients with a history of myocardial infarction85.  
1.4 Animal models of atherosclerosis 
Atherosclerosis animal models have been developed to understand the 
cellular and molecular mechanisms of atherosclerosis pathogenesis, and to drive 
research that evaluates the efficacy of newly developed preventive and therapeutic 
atherosclerotic drugs86. Animal models used to study atherosclerosis and 
thrombosis include: mouse, rat, rabbit, and pig87. The majority of animal models 
are based on the presence or induction of hyperlipidemia, primarily 
hypercholesterolemia, which is the most important risk factor influencing 
atherosclerosis development. In 1908, Ignatowski demonstrated that the 
experimental atherosclerosis could be induced in animals, when he fed rabbits a 
diet enriched in animal proteins including milk, eggs, and meat. At the experimental 
endpoint, these rabbits presented with atherosclerotic lesions in the aortic wall41,44. 
After that, several animal models were employed to understand the mechanisms 
involved in both induction and regression of atherosclerotic lesions87,88.   
Recently, the mouse models have become the most commonly used animal 
model for atherosclerosis experimentation. These animal models are easy to 
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handle, inexpensive to maintain, reproduce quickly, and are easily to genetically 
manipulate89,90. The development of atherosclerosis in mice is typically based on 
genetic modifications of lipoprotein metabolism, including deletion of LDL-receptor 
(LDLR) or apolipoprotein-E (apoE) gene, followed by administration of a high fat 
diet to induce hyperlipidemia. High-fat diet (HFD) in experimental research has 
been found to elevate serum LDL and atherosclerosis in different atherosclerotic 
animal models, including mice91. The apoE-deficient (apoE−/−) mice and LDLR-
deficient (LDLR−/−) mice are the most widely used murine models92,93. 
Apolipoprotein-E is a plasma lipoprotein secreted from liver and promotes hepatic 
binding, uptake, catabolism, and clearance of triglyceride-rich lipoproteins such as 
very low density lipoprotein (VLDL) and low density lipoprotein (LDL)94. In apoE−/− 
mice, the total plasma cholesterol levels are dramatically increased and extensive 
atherosclerotic lesions form (widely distributed throughout the aorta) even in the 
absence of cholesterol– enriched diet, where lesions progress and advance with 
age95. LDLR is a cell-surface receptor expressed in different cell types, where they 
pick up low-density lipoproteins circulating in the bloodstream and transport them 
into the cell. They are particularly abundant in the liver that mediates the 
endocytosis of LDL particles, thereby removing excess LDL-cholesterol from the 
circulation. LDLR expression is tightly controlled by feedback mechanisms at the 
transcriptional and post-transcriptional levels. When intracellular cholesterol levels 
are highly elevated, the transcription factor, sterol regulatory element-binding 
proteins (SREBPs) will down-regulate the rate-limiting enzyme of cholesterol 
biosynthesis (HMG-COR), as well as the LDLR, and scavenger receptor class B 
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member 1 (SCARB1)96. Therefore, LDLR−/− mice exhibit a delayed clearance and 
consequently, massive accumulation of plasma LDL93. Thus, the LDLR−/− mouse 
model is characterized by elevated plasma cholesterol levels and develop 
atherosclerotic lesions slowly when fed a normal chow diet. When fed HFD, 
LDLR−/− mice develop hypercholesterolemia and extensive lesions throughout the 
entire aorta and aortic root97.  
1.5 Bone marrow transplantation and total body irradiation 
Lethal total body irradiation of atherosclerotic mice followed by bone marrow 
transplantation from donor mice with transgenic alterations in the innate and 
adaptive immune systems is a common method utilized to reconstitute the immune 
system and experimentally used to identify the role of bone marrow-derived cells 
in atherosclerosis. The experimental mice are compared to control mice that have 
undergone comparable irradiation and bone marrow transplantation with 
syngeneic wild-type bone marrow cells98. This technique is commonly used in 
atherosclerosis research to determine the contribution of different hematopoietic 
cells of interested genotype to the pathogenesis of atherosclerosis99. The high 
dose total body irradiation is to completely deplete the hematopoietic system of the 
recipients and to make sure the engraftment of the bone marrow cells from the 
donors. Because the total body irradiation causes damage to the small intestine, 
the recipient mice should be provided with antibiotics one week before and two 
weeks after bone marrow transplantation to avoid septic shock caused by the 
intestinal bacteria crossing into the blood stream due to their suppressed immune 
system100. LDLR−/− mice are the most common mouse model used as recipient 
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mice. ApoE−/− mice are not commonly used as the recipients, because ApoE 
produced by the transplanted bone marrow cells are sufficient to reverse the 
atherogenic phenotype101. After bone marrow transplantation, mice were allowed 
4 – 5 weeks to reconstitute the hematopoietic and immune system. After this 
period, majority of the myeloid cells in peripheral blood and bone marrow will be a 
donor derived cells98.  
1.6 microRNA-155 in atherosclerosis 
MicroRNAs (miRNAs) are small, noncoding RNA molecules that regulate 
gene expression at the post-transcriptional level through base pairing with mRNAs, 
resulting in either translational repression or mRNA degradation. The expression 
and targets of miRNAs are cell type dependent, which determines the biological 
function of miRNAs102,103. microRNA-155 (miR155), a typical multi-functional 
miRNA, has recently emerged to play a significant role in atherosclerosis 
development104. It has been shown that a hematopoietic miR-155 deficiency 
reduced atherosclerosis in partial carotid artery ligation Apoe–/– mouse model by 
increasing the expression of B-cell leukemia/lymphoma 6 (Bcl6) in macrophages 
thus reducing vascular inflammation105. Additionally, miR155 inhibition by 
antagomirs in Apoe–/– mice significantly reduced lesion formation after high-fat diet 
feeding106.  However, hematopoietic miR155 deficiency increased atherosclerosis 
in LDLR−/− mice fed a high-fat diet by generating a more pro-atherogenic immune 
cell profile and a more pro-inflammatory monocyte/macrophage phenotype107. 
Previously we showed that miR155 deficiency in apoE−/− mice attenuated 
atherogenesis by reducing macrophage inflammation108.  
17 
 
My studies aim to further investigate the inflammation hypothesis of 
atherosclerosis in human atherosclerotic carotid lesions as well as in 
atherosclerotic mouse models. We measured the expression levels of 
inflammation markers in human carotid atherosclerotic lesions and studied the role 
of microRNA-155 in vascular calcification. We also studied the role of tristetraprolin 
(TTP) in inflammation and atherosclerosis. Additionally, we examined the effect of 
macrophage-specific GP96 deficiency on inflammation and atherosclerosis 
development. Finally, we examined the therapeutic value of an anti-inflammatory 
— Chinese herb compound, SsnB, for atherosclerosis. 
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Chapter II 
Inflammation markers in human atherosclerotic lesions and the role of 
microRNA-155 in vascular calcification 
2.1 Background 
Inflammation plays a critical role in all stages of atherosclerosis: endothelial 
activation resulting in a chemokine-mediated recruitment of different immune cells; 
modification and uptake of oxLDL by macrophages and defective cholesterol efflux 
leading to formation of foam cells and fatty streaks in the early stage of 
atherosclerosis. Over time, the disease progresses and complex fibrotic plaques 
are produced as a result of foam cell death, migration and proliferation of VSMCs 
and a continued inflammatory response. The production of ECM by VSMCs leads 
to stabilization of plaques, whereas the production of matrix metalloproteinases 
(MMPs) from macrophages resulted in destabilization and rupture of unstable 
plaques and subsequently thrombosis and clinical complications (e.g. myocardial 
infarction)31,51,109. The inflammatory response in atherosclerosis is regulated by 
both the innate and adaptive immune system coordinated by different cytokines110. 
Knowledge of the roles of cytokines in all stages of atherosclerosis has recently 
advanced considerably mainly by studies using mouse model systems51,110,111. 
Therefore, investigating the role of the immune system in the progression of 
atherosclerosis and reducing inflammation represent a potential novel therapeutic 
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approach for prevention and treatment of atherosclerotic vascular diseases. The 
inflammatory cytokine IL1β is the central cytokine in the inflammatory response in 
atherogenesis which drives IL6 signaling pathway. The CANTOS study using 
Canakinumab, IL-1β neutralizing antibody validated the role of inflammation in 
CVDs and revealed a significant 15% reduction of major adverse cardiovascular 
events in patient with a prior heart attack and inflammatory atherosclerosis83,84.  
The expression of inflammatory markers in human atherosclerotic plaques 
has been studied since 1985 using different techniques including RT-PCR, 
immunohistochemistry, and in situ hybridization112. Interleukin 1-β (IL-1β) and 
interleukin 6 (IL-6) expression have been observed in atherosclerotic lesions in 
humans, hypercholesterolemic rabbits, and apoE−/− mice and their roles in nearly 
all phases of atherosclerosis have been widely documented, indicating the pro-
inflammatory role of these cytokines113,114. We recently demonstrated a pro-
atherogenic role of microRNA-155 (miR155) in mouse models115. However, if the 
pro-atherogenic role of miR155 also holds true in humans has not been examined. 
 In the current study, we performed qRT-PCR to examine the expression 
levels of inflammation markers including — IL-6, IL-1β, miR155, MMP-9, 
Adiporedoxin (Adrx) in human atherosclerotic carotid arteries in different locations 
— normal media, diseased media, atheroma, and fibrous cap from patients 
undergoing surgical carotid endarterectomy. Furthermore, the expression of 
miR155 and its correlation to osteogenic genes in calcified media have been 
examined. In our study, we demonstrated that most of the inflammatory markers 
listed above were significantly up-regulated in atheroma, fibrous cap, and diseased 
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media of the carotid plaque and that miR155 positively correlated with IL-6, IL-1β, 
and MMP-9. We showed that miR155 expression was significantly increased in the 
fibrous caps of lesions in symptomatic patients compared to those in a- 
symptomatic patients. We also showed that miR155 expression is increased in 
calcified media and its expression levels positively correlates with osteogenic 
genes, which are confirmed in cell culture and in vivo animal studies. We found 
that miR155 deficiency significantly attenuated VSMCs and aortic calcification 
induced by calcification media and reduced osteogenic gene expression. 
Compared to wildtype mice, miR155 deficient mice showed a significant decrease 
in vascular calcification induced by vitamin D3 (vitD3).  
2.2 Material and Methods 
Human carotid atherosclerotic specimens 
Human carotid artery specimens were collected from symptomatic or a 
symptomatic carotid atherosclerotic patients undergoing carotid endarterectomy (n 
= 81) with patients' informed consent at Greenville Memorial Hospital (Greenville 
health system, Greenville, SC, USA) and Palmetto Hospital (Palmetto Health 
System, Columbia, SC, USA). Specimens were sliced transversely into 7 mm 
segments. One segment from each specimen was dissected into separate 
samples representing normal media, atheroma, underlying diseased media, and 
fibrous cap.  
Vascular smooth muscle cell isolation and culture 
Vascular smooth muscle cells were isolated from wild-type or miR155−/− 
mice using collagenase digestion as previously described116. The isolated cells 
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were cultured in DMEM supplemented with 10% fetal bovine serum, penicillin-
streptomycin, and 2 mM L-glutamine. Cells passage five were used in all of the 
experiments. To induce calcification, cells were cultured in calcification media (2 
mM CaCl2, and 2 mM inorganic phosphate) for 7 days. Calcification media was 
changed every other day.  
RNA extraction, cDNA synthesis, and quantitative real-time PCR 
Quantitative real-time PCR (qRT-PCR) was utilized to measure the 
expression levels of human interleukins (IL-6 and IL-1β), matrix metalloproteinase-
9 (MMP-9), and miR-155, Adiporedoxin (Adrx), and osteogenic genes (OPN, BMP-
2, RUNX-2, and COL-1) in carotid artery specimens. Total RNA, including miRNAs, 
were isolated from cultured VSMCs or human specimens after homogenization in 
Qiazol lysis reagent (Qiagen, Maryland, USA) using miRNeasy Mini kit (Qiagen, 
Maryland, USA) and reverse transcribed to cDNA using miScript-II Reverse 
Transcription Kit (Qiagen, Maryland, USA). qRT-PCR was performed using 
miScript SYBR Green PCR Kits (Qiagen, Maryland, USA). Human inflammatory 
gene expression was normalized with 18S as endogenous control. miR155 
expression was detected according to the manufacturer’s instructions using the 
miScript PCR System (Qiagen, Valencia, CA, USA) and miScript Primer Assays 
(Qiagen, Maryland, USA). Human miR155 gene expression was normalized to U6 
as endogenous control. Gene expression levels are reported as ΔCt values relative 
to expression of 18S or U6. ΔCt is the difference in threshold cycle between the 
gene of interest and the housekeeping gene (18S or U6) as a control.  ΔCt levels 
are inversely proportional to the gene expression in the sample (the lower the ΔCt 
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level the greater the higher expression of target gene in the sample). Primers used 
are listed in table 2.1. 
Aortic ring culture 
Aortas were dissected from wild-type or miR155−/− mice, cut into small rings, 
then cultured in calcification media which was changed every other day. After 7 
days, aortic rings were harvested for calcium content quantification and embedded 
in optimal cutting temperature (OCT) compound (Sakura Finetek USA, Inc., 
Torrance, CA, USA) for frozen section and Alizarin Red staining for calcium 
deposition. 
Induction of vascular calcification in mice 
Twenty week-old male C57BL/6J mice and miR155−/− mice (n=5 for each 
group) were used to induce vascular calcification by administration of Vitamin D3 
(VitD3) — Cholecalciferol (Sigma Aldrich, St. Louis, MO, USA). VitD3 was 
dissolved in absolute ethanol (5 mg per 40 μL) then diluted to a concentration of 
3.75 mg/mL with highly refined olive oil (Sigma Aldrich, St. Louis, MO, USA). Stock 
solutions of VitD3 were prepared fresh for each 3-day injection cycle and then 
placed in foil wrapped containers and stored at 4°C. The mice were 
intraperitoneally injected with a dose of VitD3 (100 μL/30 g body weight, 500000 
IU/kg, per day) or vehicle (100 μL olive oil, per day) for 10 days. On the 14th day 
after injection, blood and aorta tissues were harvested for further analysis. 
Calcium content quantification 
After decalcification with 0.6 N HCl at 4 ℃ for 24 hour, the calcium content 
from cells and tissues were determined in the HCl supernatants using colorimetric 
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assay with calcium assay kit (QuantiChromTM Calcium Assay Kit, BioAssay 
Systems, Hayward, CA, USA) according to the manufacturer’s instructions. Briefly, 
5 μL of the samples was added to a 96-well plate. 200 μL of working reagent was 
added and absorbance was measured at 570 nm using a microplate ELISA reader 
(BioTek Instruments, Winooski, VT, USA). After decalcification, cells were washed 
three times with PBS and solubilized with 0.1 N NaOH/0.1% SDS. The protein 
content was measured with a DCTM Protein Assay kit (Bio-Rad). The calcium 
content of VSMCs was then normalized to the protein content, whereas that of the 
tissues was normalized to tissue dry weight.  
For serum calcium measurement, blood was collected from mice by retro-
orbital venous plexus puncture, serum obtained via centrifugation at 4000 x g for 
20 minutes. Serum calcium concentration was measured using the QuantiChrom 
calcium assay kit (BioAssay Systems, Hayward, CA, USA) according to the 
manufacturer’s instructions.    
Alizarin Red S staining 
Slides were hydrated with Xylene/Alcohol and washed three times with tap 
water. Slides were stained in 1% Alizarin Red S solution (Sigma Aldrich, St. Louis, 
MO, USA) at pH 9.0 for 30 minutes. Next, slides were dehydrated in Acetone for 
15 seconds, then in Acetone/Xylene for 15 seconds. Then slides were cleaned in 
3 Xylene changes, coversliped and visualized under microscope to detect vascular 
calcium deposition. 
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Western blot analysis 
To obtain the total cell lysates, cells were incubated and lysed for 30 
minutes on ice in RIPA buffer (PierceTM, Rockford, IL, USA) supplemented with 
protease inhibitor cocktail and phosphatase inhibitors (Sigma, Sigma Aldrich, St. 
Louis, MO, USA). Equal amount of total cell proteins (30 µg) were separated by 4-
20% SDS–polyacrylamide gel electrophoresis (Bio-Rad) and transferred onto 
nitrocellulose membranes (Millipore Corp., Bedford, MA, USA). After blocking with 
5% fat-free milk solution, primary antibodies and HRP-conjugated secondary 
antibodies were used to detect the protein of interest. The primary antibodies used 
were as follows: anti-RUNX2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
anti-OPN (Bioworld Technology, MN, USA), and anti-GAPDH (GeneTex, Irvine, 
CA, USA). Signal was detected using Pierce ECL Western Blotting Substrate 
(PierceTM, Rockford, IL, USA) and exposed to X-ray film to obtain optimal results 
in the dark room. The density of blots was quantified by Image-Pro Plus 6.0 
software. For stripping, membranes were submerged for 30 minutes at 55 – 60°C 
in a buffer containing 100 mM 2-mercaptoethanol, 2% SDS and 62.5 mM Tris-HCl, 
pH 6.7, and washed three times with PBST.  
Statistical analyses 
Statistical analysis was performed with Graph-Pad Prism 6.0 software 
(Graph-Pad Software Inc, San Diego, CA, USA). Statistical significance was 
determined using one-way analysis of variance (ANOVA). The correlations 
between expression of inflammatory genes and miR-155 expression were 
analyzed by linear regression. For mouse experiments, All measurement data 
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were expressed as the mean ± standard error of the mean (SEM). Statistical 
differences were determined using a Student’s t-test for two group comparisons 
and one-way analysis of variance (ANOVA) for multiple group comparison. Data 
were considered statistically significant at *P < 0.05, **P<0.01, and ***P<0.001.  
2.3 Results 
Increased expression of inflammatory cytokines in human carotid 
atherosclerotic lesions 
First, we examined the expression levels of IL-6 and IL1-β in human 
atherosclerotic carotid artery using qRT-PCR. Atheroma, underlying diseased 
media, fibrous cap covering the atheroma, and the surrounding normal media from 
human atherosclerotic carotid artery were dissected and total RNA was extracted 
for measurement of human IL-6 and IL1-β expression. In agreement with the 
growing body of literature that demonstrates the higher expression of inflammatory 
cytokines in atherosclerotic plaques114,117,118, our results showed that IL-6 and IL-
1β mRNA expression levels were significantly increased in human carotid plaques. 
The expression of IL-6 (Figure 2.1A and 2.1B) and IL-1β (Figure 2.1C and 2.1D) 
in different locations of the lesion — atheroma, underlying diseased media and 
fibrous cap were significantly higher compared to surrounding normal carotid 
media in atherosclerotic carotid artery for the same patient (p<0.05).  
Increased expression of matrix metalloproteinase-9 (MMP-9) in human 
carotid atherosclerotic lesions 
In addition to the uptake of lipoproteins, macrophages secrete inflammatory 
mediators and proteinases such as matrix metalloproteinases (MMPs), which play 
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a critical role in atherosclerotic plaque progression22. Collagen, a key component 
in the fibrous cap of atherosclerotic plaques, helps maintain the plaque stability. 
MMPs degrade collagen, leading to increased plaque instability119. Therefore, 
inflammation and MMPs contribute to all phases of atherosclerosis, from initiation 
through progression and eventually to the thrombotic complications. MMP-9 
represents a novel inflammation marker in coronary artery disease patients and its 
expression is found to be increased in advanced lesions in atherosclerotic mouse 
models and in progressive carotid atherosclerotic plaques obtained from humans 
undergoing carotid endarterectomy, especially in the fibrous cap regions where 
macrophages accumulate, implicating MMP-9 and macrophages in plaque 
rupture120,121. Our data showed that MMP-9 expression was significantly increased 
in atheromatous tissue, diseased media and fibrous caps of human atherosclerotic 
carotid plaques compared to the adjacent normal media of the same patient 
(Figure 2.1E and 2.1F) (p<0.001).  
Increased expression of Adiporedoxin in atheroma tissue of human carotid 
atherosclerotic plaques 
Adiporedoxin (Adrx) is a redox regulatory protein that is expressed in 
adipose tissue and plays a critical role in the adipocyte function and regulates 
metabolism by modulating secretion of adiponectin that protect from the 
development of diabetes and heart disease122. Adrx has been shown to have anti-
inflammatory effects by negatively regulating macrophage inflammation123. 
Recently, it has been shown that Adrx was expressed in human vascular 
endothelial cells, and its expression significantly induced by oxLDL, IL-1β, and 
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TNF-α stimulation124. In this study, we examined expression of Adrx in atheroma 
tissue from human carotid atherosclerotic plaques. We found that Adrx expression 
was significantly increased in the atheroma compared to normal tissue from the 
same carotid arteries (Figure 2.1G) (p<0.05). These results suggest induction of 
Adrx expression may serve as an intrinsic anti-atherogenic mechanism which can 
be exploited for atherosclerosis treatment. 
miR155 expression is up-regulated in human carotid atherosclerotic lesions 
miR155 has been shown to enhance macrophage inflammation and proved 
to be pro-atherogenic115. Recently, we and others showed that the macrophage 
miR155 may be pro-atherogenic115,125. We therefore examined the miR155 
expression in different locations of human carotid atherosclerotic plaque and 
compared to the normal media in the same arteries. In agreement with these 
previous studies, we demonstrated that miR155 expression levels were 
significantly up-regulated in the atheroma, underlying diseased media, and fibrous 
cap compared to the adjacent normal media (Figure 2.2A and 2.2B)(p<0.05). 
Moreover, the expression levels of miR155 were compared in the fibrous caps from 
a-symptomatic (n=69) and symptomatic (n=12) patients. The results showed that 
fibrous caps obtained from symptomatic patients were characterized by 
significantly higher expression levels of miR155 compared to those from a- 
symptomatic patients (Figure 2.2C) (p=0.0331).  
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Expression levels of miR155 positively correlate with the expression of 
inflammatory cytokines and MMP-9 in human carotid plaques  
To test whether the expression levels of miR155 are correlated with pro-
inflammatory cytokine expression, we analyzed the correlation between miR155 
expression and the expression of inflammation markers; IL-1β, IL-6, and MMP-9 
using linear regression. Gene expression levels of inflammation markers, IL-6, IL-
1β as well as MMP-9 in human carotid plaques showed highly significant positive 
correlations with miR155 expression levels (r=0.377, r=0.238, r=0.432 
respectively, p<0.0001) (Figure 2.3A, 2.3B, and 2.3C) suggesting that increased 
miR155 expression is associated with more inflammation and plaque instability in 
human carotid atherosclerotic diseases.  
miR155 expression is up-regulated in calcified media and positively 
correlated with osteogenic genes 
Cardiovascular calcification is a major feature of chronic inflammatory 
disorders — such as atherosclerosis and calcific aortic valve disease (CAVD) — 
that associate with increased mortality and morbidity126. There has been evidence 
that specific miRNAs such as miR-125b, miR-133a, miR-29a/b, miR-204, and miR-
30b/c — play critical roles in the regulation of vascular calcification, in vitro and in 
vivo by regulating the trans-differentiation of VSMCs to osteoblast-like cells127–131. 
The role of miR155 in vascular calcification has never been studied. In the current 
study, we examined the expression levels of miR155 in calcified media and 
correlated that with the expression levels of calcification markers. The results 
showed that miR155 was highly expressed in calcified media compared to 
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adjacent normal non-calcified media, p=0.0356 (Figure 2.4A). Concurrently, we 
examined the expression levels of some calcification (osteogenic) genes, such as 
Osteopontin (OPN), Bone morphogenetic protein-2 (BMP-2), Runt-related 
transcription factor-2 (RUNX-2), and Collagen Type I Alpha 1 (COL-1). The 
expression levels of these genes were significantly up-regulated in calcified media 
compared to adjacent non-calcific media, p<0.05 and p<0.01 (Figures 2.4B, 2.4C 
2.4D and 2.4E). Next, we analyzed the correlation between expression of miR155 
and osteogenic genes. We plotted the correlation of miR155 levels and OPN, 
BMP-2, or RUNX-2 levels, showing a clear positive correlation between expression 
levels of miR155 with OPN and RUNX-2 expression levels (r=0.446, r=0.322 
respectively) (Figure 2.4F). Thus, miR155 seems to influence plaque stability by 
influencing the expression levels of osteogenic genes, and thus the grade of 
calcification. 
miR155 deficiency attenuates VSMCs calcification in vitro  
To further study the role of miR155 in vascular calcification and to confirm 
the data obtained using human samples, mouse VSMCs were isolated from aorta 
of wild-type or miR155−/− mice, cultured in DMEM media supplemented with 5% 
FBS, penicillin/streptomycin, and treated with calcification media containing 2 mM 
CaCl2 and 2 mM of inorganic phosphate (Pi) to induce calcification. Calcification 
media was changed every other day. After seven days, cells were collected, 
cellular calcium content was measured. miR155−/− VSMCs showed a significant 
decrease in calcium deposition compared to wild-type VSMCs (Figure 2.5A). Then 
cells were lysed in Trizol for mRNA extraction. The mRNA expression levels of 
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osteogenic genes including BMP-2, RUNX-2, OPN and OCN were detected. The 
results showed that the expression of these genes was significantly increased after 
calcification media treatment and that the miR155−/− VSMCs had a lower 
expression than the wild-type VSMCs, p-value<0.05 (Figure 2.5B). This result 
indicated that miR155 deficiency significantly reduced expression of osteogenic 
genes in calcified VSMCs. Furthermore, we measured the protein levels of RUNX-
2 and OPN. The results showed that miR155 deficiency significantly reduced 
protein expression levels of RUNX-2 and OPN (Figure 2.5C). These data indicated 
that miR155 deficiency attenuated VSMCs calcification by reducing expression of 
osteogenic genes.  
miR155 deficiency attenuates aortic calcification ex vivo and in vivo 
 The effect of miR155 on vascular calcification was further assessed ex vivo 
and in vivo. The aortas were dissected from miR155−/− or wild-type mice, cut into 
rings, and cultured in calcification media. Also, aortas from mice injected with vitD3 
were dissected and cut into small rings. The degree of calcification was determined 
using alizarin-red staining and tissue calcium content was detected using 
colorimetric assays with calcium assay kit. The results demonstrated that miR155 
deficiency reduced calcium tissue content and calcium deposition in the calcified 
cultured aortic ring (Figures 2.6A and 2.6B) and aortic ring from vitD3 injected mice 
(Figures 2.6C and 2.6D). We also measured serum calcium concentration after 
vitD3 injection. Interestingly, miR155−/− mice displayed higher serum calcium than 
wild-type mice p-value<0.05 (Figure 2.6E). Collectively, these data indicated that 
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miR155 deficiency reduced aortic calcification ex vivo and in the aorta of vitD3 
injected mice. 
2.4 Discussion 
Inflammation plays a significant role in all stages of atherosclerosis. The 
cytokines secreted by innate and adaptive immune cells regulate the inflammatory 
response in atherosclerosis22,31. The expression of inflammatory cytokines in 
mouse models of atherosclerosis has been extensively studied. A previous study 
found that the expression of the pro-inflammatory cytokines in apoE−/− mice after 
4 weeks of high fat diet was significantly increased132. The expression levels of 
several pro-inflammatory cytokines in the atherosclerotic plaques were studied 
and reported from the mid-1980s mainly in human carotid endarterectomy 
specimens112. Better understanding of cytokine gene expression is important for 
successful development of therapeutic approaches that decrease the inflammatory 
response. Inhibiting cytokine-induced inflammation and promoting the anti-
inflammatory cytokine response represent potential therapeutic approaches for the 
prevention of disease development and progression. Currently available therapies 
against atherosclerosis are mainly lipid modulators. While lipid lowering drugs are 
successful at reducing the risk of death result from cardiovascular diseases, there 
is a need for new therapies that directly target the inflammation to further attenuate 
atherosclerosis and improve cardiovascular outcome133.  
The expression of inflammation markers in different locations in the human 
carotid plaque has not been addressed. In our study we examined the mRNA 
expression levels of some inflammation markers in human carotid atherosclerotic 
  
32 
arteries obtained from patients undergoing carotid endarterectomy. The 
specimens were dissected into atheroma, underlying diseased media, fibrous cap, 
and the surrounding non-diseased media. The expression levels of inflammation 
markers (such as IL-6, IL-1β, MMP-9, miR155, and Adiporedoxin) and calcification 
markers (such as OPN, RUNX-2, BMP-2, and COL-1) were measured. IL-6, a pro-
inflammatory cytokine mainly expressed by activated macrophages and VSMCs, 
was significantly higher in atheroma, diseased media, and in the fibrous cap 
compared to the normal non-diseased media. Similarly, expression of pro-
inflammatory cytokine IL-1β was significantly higher in atheroma, diseased media, 
and in the fibrous cap compared to the normal non-diseased media. The 
expression level of MMP-9 was higher in atheroma, diseased media, and in the 
fibrous cap compared to the normal non-diseased media. Furthermore, the 
expression level of miR155, a recently reported pro-inflammatory and pro-
atherogenic microRNA, was significantly up-regulated in the atheroma, diseased 
media, and fibrous cap compared to the normal media. Increased expression of 
these mRNAs in different locations in human carotid atherosclerotic plaque 
suggests they may play a role in atherosclerotic plaque progression. Furthermore, 
when we analyzed the expression levels of miR155 in the fibrous caps in 
symptomatic patients compared to asymptomatic patients, we found that the 
expression levels of miR155 in fibrous cap were significantly higher in symptomatic 
compared to those in asymptomatic patients. This might suggest the important role 
of miR155 in modulating plaque stability and clinical manifestation of plaque 
rupture. The expression of miR155 and calcification markers — such as OPN, 
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RUNX-2, Col-1, and BMP-2 in calcified media were also analyzed. The results 
showed that miR155 was up-regulated in calcified media occurred concomitant 
with increased expression levels of calcification markers, suggesting miR155 
might be involved in vascular calcification. Moreover, we showed a positive 
correlation between miR155 expression level and osteogenic gene expression 
levels. We also used in vitro, ex vivo, and in vivo experiments to determine the 
effect of miR155 deficiency on vascular calcification. The results showed that 
miR155 deficiency attenuated vascular calcification in VSMCs after calcification 
media treatment as well as decreased aortic calcification in vitD3 injected mice. 
Furthermore, the expression levels of osteogenic genes in miR155−/− VSMCs after 
treatment with calcification media were significantly reduced compared to wild-type 
VSMCs. These results were in agreement with the data obtained from human 
samples as the increased miR155 expression levels in calcified media occurred 
concomitant with increased expression levels of osteogenic genes. Collectively, 
these data indicated that miR155 plays a critical role in VSMCs calcification by 
increasing expression of osteogenic genes, and inhibiting miR155 may represent 
a novel approach to reduce vascular calcification. Inhibition of miR-155 by 
antagomiR-155 may provide new therapeutic approach for the prevention and 
treatment of vascular calcification caused by a variety of diseases. Investigating 
the role of miRNAs in VSMCs calcification will lead to a better understanding of 
the mechanisms and to developing drugs directed against specific gene targets for 
the treatment of cardiovascular diseases associated with vascular calcification. 
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Table 2. 1 Primers that were used for qRT-PCR in this study 
 
Primers Forward (5’  3’) Reverse (5’  3’) 
18s CGCGGTTCTATTTTGTTGGT AGTCGGCATCGTTTATGGTC 
hIL-6 TACCCCCAGGAGAAGATTCC TTTTCTGCCAGTGCCTCTTT 
hIL-1β GGGCCTCAAGGAAAAGAATC TTCTGCTTGAGAGGTGCTGA 
hMMP-9 GATGACGAGTTGTGGTCCCT GCCTTGGAAGATGAATGGAA 
hOPN CTCCATTGACTCGAACGACTC CAGGTCTGCGAAACTTCTTAG
AT 
hRUNX2 TGGTTACTGTCATGGCGGGTA TCTCAGATCGTTGAACCTTGC
TA 
hBMP2 ACCCGCTGTCTTCTAGCGT TTTCAGGCCGAACATGCTGAG 
hCOL-1 GAGGGCCAAGACGAAGACAT
C 
CAGATCACGTCATCGCACAAC 
mBMP2 GGGACCCGCTGTCTTCTAGT TCAACTCAAATTCGCTGAGGA
C 
mRUNX
2 
GACTGTGGTTACCGTCATGG
C 
ACTTGGTTTTTCATAACAGCG
GA 
mOCN CTGACCTCACAGATCCCAAG
C 
TGGTCTGATAGCTCGTCACAA
G 
mOPN AGCAAGAAACTCTTCCAAGC
AA 
GTGAGATTCGTCAGATTCATC
CG 
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Figure 2. 1 Increased expression of inflammation markers in human carotid 
atherosclerotic atheroma  
Carotid artery plaque samples of patients undergoing carotid endarterectomy were 
collected. mRNA was isolated from tissue extracts and mRNA transcripts of genes 
of interest were measured by qRT-PCR. Results were represented as ΔCt values 
after being normalized to the expression of 18s rRNA. ΔCt is the difference in 
threshold cycle between the gene of interest and the housekeeping gene (18s 
rRNA).  ΔCt levels are inversely proportional to the gene expression levels (the 
lower the ΔCt level, the higher expression of target gene). (A, B) IL-6 mRNA, (C, 
D) IL-1β mRNA, (E, F) MMP-9, and (G) Adrx mRNA in different locations for the 
same patients were detected. Each line connects data from a same patient 
(*p<0.05, **p<0.01, ***p<0.001)  
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Figure 2. 2 Increased expression of miR155 in human carotid atherosclerotic 
plaques  
Carotid artery plaque samples of patients undergoing a carotid endarterectomy 
were collected. mRNA was isolated from tissue. miR155 mRNA levels were 
measured using qRT-PCR. Results were represented as ΔCt values after being 
normalized to the expression of U6. ΔCt is the difference in threshold cycle 
between miR155 and U6. (A, B) Expression levels of miR155 were significantly 
increased in atheroma, diseased media, and fibrous cap from human carotid 
lesions, compared to those in the normal media. Each line connects data from a 
same patient. (*p<0.05, **p<0.01, ***p<0.001). (C) Expression of miR155 in fibrous 
cap of carotid atherosclerotic plaques is higher in symptomatic than asymptomatic 
patients. (*p=0.033). 
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Figure 2. 3 Expression levels of miR155 correlate with the levels of 
inflammatory cytokines and MMP-9 in human carotid artery atheroma 
 Correlation between miR155 expression and pro-inflammatory cytokines IL6 (A), 
IL1β (B), and miR155 expression and MMP-9 expression (C) using linear 
regression.  
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Figure 2. 4 The expression of miR155 and calcification gene in human 
atherosclerotic carotid artery  
(A) The expression level of miR155 in human atherosclerotic carotid artery was 
assessed by qRT-PCR (n=6 for each group). Results were represented as ΔCt 
values after being normalized to the expression of U6. (B, C, D, and E) the 
expression levels of osteogenic genes including OPN, COL-1, BMP-2, and RUNX-
2 in human atherosclerotic carotid artery were assessed by qRT-PCR. Results 
were presented as ΔCt values after being normalized to the expression of 18s 
rRNA. Each line connects data from a same patient. (n=5 for each group). (F, G) 
Correlation between miR155 expression and osteogenic markers (OPN and 
RUNX2) using linear regression. *P<0.05, **P<0.01. NM: Normal media; CM: 
Calcification media 
  
40 
 
 
Figure 2. 5 miR155 deficiency attenuates calcification in vascular smooth 
muscle cells  
(A) Calcium content of VSMCs was measured using colorimetric assay with a 
calcium assay kit. The expression levels of calcification genes; BMP-2, RUNX-2, 
OPN and OCN in VSMCs after treatment with calcification media were detected 
by qRT-PCR. (C) Protein levels of RUNX2 and OPN were assessed by western 
blotting. *p<0.05 
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Figure 2. 6 miR155 deficiency attenuates aortic calcification in vivo and ex 
vivo  
(A) Calcium deposition in cultured aortic rings from wild-type or miR155−/− mice 
was detected by alizarin Red staining. (B) Quantification of calcium content in the 
aortic rings using colorimetric assays with calcium assay kit. (C) Calcium 
deposition in the aortas of wild-type or miR155−/− mice injected with VitD3 was 
determined by Alizarin Red staining. (n=5 for each group). (D) Quantification of 
aortic calcium content. (E) Serum calcium concentration was measured by 
colorimetric assay using a calcium assay kit. Scale bar, 500 μm. *P<0.05, 
**P<0.01. 
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Chapter III 
The role of Tristetraprolin (TTP) in inflammation and atherosclerosis 
3.1 Background 
Tristetraprolin (TTP) — also known as ZFP36 (zinc finger protein of 36 
kDa)134, Nup 475135, TIS11136, or G0S24137 — is member of a small family of 
mRNA-binding proteins containing a tandem Cys-Cys-Cys-His (CCCH) zinc finger 
(TZF) domain. The initial description of TTP was in 1990 in mouse 3T3-L1 
fibroblasts stimulated with insulin and serum138. This protein is encoded by the 
immediate – early response gene called Zinc Finger Protein 36 (ZFP36)139. It is 
highly expressed in immune organs in a variety of cell types including monocytes 
and macrophages138. Normally, TTP protein levels are low and the protein is 
primarily localized in the nucleus of quiescent cells. However, mitogenic 
stimulation of cells induces TTP expression and promotes rapid translocation from 
the nucleus into the cytoplasm140. Through the TZF domains, TTP can binds 
directly to the adenosine-uridine (AU)-rich elements (AREs) in the 3’ untranslated 
region (3′-UTRs) of their target mRNAs removing its poly(A) tail; in a process 
known as ‘deadenylation’— the rate-limiting step in mRNA decay resulting in 
suppression of translation, destabilization and subsequently degradation of the 
mRNA transcript through the recruitment of deadenylases or exonucleases141,142. 
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TTP acts at the post-transcriptional level to inhibit the expression of a number of 
pro-inflammatory cytokine/chemokines and growth factors. The most apparent 
physiological targets of TTP are the mRNAs encoding TNF-α143–145, granulocyte-
macrophage colony-stimulating factor (GM-CSF)146, Interleukin-2 (IL-2)147, 
interleukin-3 (IL-3)148, Interleukin-10 (IL-10)149, Interleukin-12 (IL-12)150, and 
Interferon-γ (IFN-γ)151. The role of TTP as an mRNA destabilizing protein initially 
comes from the characterization of TTP knockout mice, which appeared normal 
and healthy at birth, but after few weeks displayed a complex inflammatory 
syndrome manifested by growth retardation, erosive poly-articular arthritis, 
conjunctivitis, dermatitis, myeloid hyperplasia, splenomegaly, kidney lesions and 
autoimmunity152. This inflammatory phenotype was due to excess production of 
the potent pro-inflammatory cytokine, TNF-α145. Furthermore, macrophages 
isolated from the TTP knockout mice and stimulated with lipopolysaccharide (LPS) 
showed a significant increase in TNF-α mRNA and protein levels due to 
stabilization of TNF-α mRNA145,153. The inflammatory phenotype of TTP knockout 
mice was significantly attenuated by injecting the mice, soon after birth, with anti-
TNF-α antibodies or by breeding with TNF-α receptor deficient mice143,154. 
To determine whether the excess TNF-α which causes the TTP deficiency 
inflammatory phenotype is produced by myeloid cells, myeloid-specific TTP 
deficient mice have been generated. Results revealed that mice with myeloid-
specific TTP deficiency appeared normal under laboratory conditions. However, 
when these mice were challenged with low-dose LPS, they developed severe 
endotoxic shock associated with increasing serum TNF-α levels compared to the 
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control mice. These studies demonstrated that myeloid cell-specific TTP deficiency 
did not completely phenocopy whole-body TTP deficiency in mice under normal 
laboratory conditions suggesting that other cell types were involved in the 
pathogenesis of the TTP deficiency syndrome155,156. Bone marrow transplantation 
has been used to determine if it could transfer the inflammatory phenotype of TTP 
knockout mice to recipient mice. Recombination activating gene-2 knockout (RAG-
2−/−) mice transplanted with TTP deficient bone marrow cells reproduce the TTP 
deficiency inflammatory syndrome, which may indicate that hematopoietic cells 
play a significant role in excess production of TNF-α that leads to the pathology 
reported in TTP knockout mice153. Recently, it has been shown that TTP is a potent 
modulator of TNF-α secretion from dendritic cells after LPS stimulation157,158.  
TTP has been shown to be highly expressed in the vascular endothelium of 
atherosclerotic mice but not in the vascular endothelium of healthy mice. The anti-
inflammatory effects of endothelial cell TTP might post it as a potential therapeutic 
target for the prevention and treatment of atherosclerosis159. 
Hematopoietic cells are crucial players in the inflammatory reactions driving 
atherosclerosis. In this study, we transplant TTP deficient bone marrow cells into 
LDLR−/− mice to examine the effect of hematopoietic TTP deficiency on 
inflammation and atherosclerotic lesion development. We investigated whether 
bone marrow transplantation transfers the inflammatory phenotype of TTP 
knockout and determine its role in atherosclerosis development in LDLR−/− mice. 
We first transplanted bone marrow cells from either TTP deficient or wild type mice 
into LDLR−/− mice after lethal irradiation, and fed a western diet for 12 weeks to 
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induce atherosclerosis. We demonstrate that TTP deficiency in bone marrow cells 
transferred the phenotype of TTP deficiency including systemic and multi-organ 
inflammation. Surprisingly, we found that TTP deficiency in bone marrow cells did 
not affect atherosclerosis development. Unexpectedly, TTP deficiency in bone 
marrow cells dramatically reduced plasma lipid and hepatic lipid accumulation 
(hepatic steatosis). Increased inflammation and attenuated hyperlipidemia offset 
each other leading to unchanged atherosclerosis in LDLR−/− mice.  
To define the role of macrophage-specific TTP deficiency on 
atherosclerosis, LDLR−/− mice were lethally irradiated and reconstituted with either 
macrophage-specific TTP deficient bone marrow cells or WT bone marrow cells. 
Four weeks after bone marrow transplantation, mice were fed a western diet for 9 
weeks. This study reveals that macrophage-specific TTP deficiency did not mimic 
the inflammatory phenotype of whole myeloid cell TTP deficiency in mice. In 
addition, these mice had comparable lesion size in the aorta and aortic root. 
Interestingly, macrophage infiltration and lipid deposition in the aortic root were 
reduced in macrophage-specific TTP deficient mice, which might be due to efficient 
removal by healthy macrophages in early atherosclerosis.  
3.2 Material and Methods 
Human carotid atherosclerotic specimens 
Human carotid artery samples were collected as described in chapter 2. 
Mice 
Six to eight week-old female LDLR−/− mice were obtained from Jackson 
Laboratories (Bar Harbor, MA, USA). Mice were maintained in pathogen-free 
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conditions at the University of South Carolina according to National Institutes of 
Health (NIH) guidelines. Animal care and experiments were approved by the 
Institutional Animal Care and Use Committee (IACUC) at the University of South 
Carolina. 
Bone Marrow Transplantation (BMT) and atherosclerosis induction in mice 
Bone marrow transplantation was performed as previously described160. 
Briefly, bone marrow cells from donor WT or TTP deficient mice were harvested 
from cleaned femurs and tibias by flushing with sterile RPMI-1640 media 
(Invitrogen Life Technologies, Grand Island, NY, USA). The cell suspension was 
centrifuged at 300 x g for 5 minutes and re-suspended in cold phosphate buffer 
saline (PBS). One week before and two weeks after BMT, recipient mice (LDLR−/− 
mice) were given autoclaved antibiotic water supplemented with 100 mg/L 
neomycin and 500,000 U/L polymyxin B sulfate. Early morning, all recipient mice 
were lethally irradiated (900 rad) using a cesium gamma source. Six hours after 
irradiation, mice were injected in the retro-orbital venous plexus with nucleated 
bone marrow cell (5 X 106 in 200 µL PBS). After BMT, mice were observed for any 
signs of bone marrow transplant rejection. To confirm the success of total body 
irradiation, one mouse did not transplanted with bone marrow cells. This mouse 
died exactly after 2 weeks of total body irradiation. After four weeks recovery, the 
resulting chimeric mice were fed a western diet for 12 weeks to induce 
atherosclerosis (Figure 3.1A). In order to assess the effect of bone marrow TTP 
deficiency in macrophages on atherosclerosis development, lethally irradiated 
LDLR−/− mice were reconstituted with macrophage-specific TTP deficient  bone 
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marrow cells or control (WT) bone marrow cells. Four weeks later, mice were put 
on western diet for 9 weeks (Figure 3.1B). During the western diet period, body 
weight and food intake were measured weekly. At the experimental endpoint, mice 
were euthanized by isoflurane and venous blood from the eyes was collected. 
Tissues including: heart, aorta, liver, lung, and spleen were collected and 
analyzed.  
Peritoneal macrophage isolation and culture 
Standard techniques were used to isolate thioglycollate-elicited peritoneal 
macrophages. Briefly, mice were injected intraperitoneally (i.p.) with 3 mL of 3% 
(w/v) sterile thioglycollate (BD Biosciences Clontech; Palo Alto CA, USA). After 3 
days, peritoneal macrophages were collected by washing the peritoneal cavity with 
10 mL of cold PBS twice. The cells were centrifuged at 300 x g for 5 minutes and 
re-suspended in high-glucose Dulbecco’s modified Eagle’s medium (DMEM, 
Invitrogen, Grand Island, NY, USA) supplemented with 10% fetal bovine serum 
(FBS), a combination of penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO, 
USA), and 50 μM of β-mercaptoethanol. Two million cells/well were cultured in a 
12-well plate. Two hours later, cells were washed with PBS to remove the non-
adherent cells, and the adherent macrophages cultured in serum free media (SFM) 
overnight at 37⁰C and 5% CO2. Macrophages were stimulated with LPS (50 ng/mL, 
Sigma-Aldrich) for 6 hours under the same conditions. Treated cells were lysed 
with Trizol reagent (Invitrogen, Grand Island, NY, USA) for mRNA extraction. 
Expressions of pro-inflammatory cytokines; TNF-α and IL-6 expression were 
detected by qRT-PCR.  
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VetScan hematology analysis 
Blood was drawn into heparinized tubes by retro-orbital puncture. Blood 
samples were run on the VetScan HMT hematology analyzer (Abaxis, Union City, 
CA, USA). The following parameters were measured: total red blood cells (RBC), 
hemoglobin, mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin 
concentration (MCHC), hematocrit (Hct), platelet number, mean platelet volume 
(MPV), platelet distribution width (PDW), total white blood cells (WBC), 
lymphocytes, mean cell volume (MCV), and red cell distribution width (RDW).  
Blood Glucose Measurement  
Blood glucose concentration was measured using OneTouch Ultra Blood 
Glucose Monitoring System (LifeScan, Inc., Milpitas, CA, USA) following the 
manufacturer’s instructions. 
Serum Lipid and Lipoprotein Analysis 
Total serum cholesterol and triglycerides were determined using enzymatic 
colorimetric assays with Cholesterol Reagent and Triglycerides GPO reagent kits 
(Raichem; San Diego, CA, USA) at the indicated time points, and analyzed by Soft-
Max Pro5 software (Molecular Devices, Sunnyvale CA, USA). In brief, mice were 
anesthetized with isoflurane, blood was collected by retro-orbital venous plexus 
puncture, plasma obtained via centrifugation at 4000 x g for 20 minutes. Serum 
was diluted 1:100 in sterile water, 100 µL was loaded on the microplate well and 
100 µL of freshly prepared cholesterol and triglyceride reagent were added to the 
wells. The plates were incubated 10 minutes at 37⁰C and the absorbance was 
measured at 540 nm. Serum lipoproteins were measured using a fast performance 
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liquid chromatography (FPLC) system (AKTA purifier, GE Healthcare Biosciences, 
Pittsburgh, PA, USA) equipped with a Superose 6 10/300 GL column (GE 
Healthcare). Pooled mouse serum (100 µL) was loaded onto the column, and 
eluted at a constant flow rate of 0.5 mL/min with 1 mM sodium EDTA and 0.15 M 
NaCI. Fractions of 0.5 mL were collected and cholesterol concentration from each 
fraction was measured.  
Total RNA extraction, cDNA synthesis, and quantitative Real-Time PCR 
Total RNAs were extracted from liver tissues and cultured peritoneal 
macrophages incubated in SFM with or without LPS stimulation using Trizol 
reagent (Invitrogen, Grand Island, NY, USA) following the manufacturer’s 
instructions. One microgram of isolated RNA of each sample was reverse 
transcribed into complementary DNA (cDNA) in 20 μL reactions using iScriptTM 
cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). qRT-PCR was performed on a 
Bio-Rad CFX96 system using iQ™ SYBR® Green Supermix (Bio-Rad) according 
to the manufacturer’s instructions. The relative amount of target mRNA was 
calculated using the 2(-ΔΔCt) method by normalizing target mRNA Ct values to those 
of housekeeping gene, 18S rRNA expression. PCR thermal cycling conditions 
were 3 minutes at 95°C, and 40 cycles of 15 s at 95°C and 58 s at 60°C. Samples 
were run in triplicate. Primers used are listed in table 3.1 
Flow cytometry analysis 
The spleen was removed from freshly euthanized mice and smashed in 10 
mL RPMI-1640 medium supplemented with 10% FBS using Stomacher® 80 
Biomaster (Seward Laboratory Systems Inc., Port St. Lucie, FL, USA). To obtain 
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single cell suspensions, tissues were passed through a 70 µM cell strainer (Life 
Sciences, Tewksbury, MA, USA). After red blood cell lysis, cells were stained for 
30 minutes on ice in dark with anti-CD19 mAb, anti-CD3 PE mAb,  anti-CD4 FITC 
mAb, anti-CD8a FITC mAb, anti-FOXP3 mAb,  anti-ly6C FITC mAb, anti-CD11b 
PE mAb, anti-ly6G FITC mAb, and anti F4/80 FITC mAb (eBioscienceTM, 
Invitrogen, Grand Island, NY, USA) in staining buffer. Stained cells were acquired 
on a Cytomics FC 500 flow cytometer and CXP software version 2.2 (Beckman 
Coulter, Brea, CA, USA). Data were collected for 10,000 live events per sample. 
Enzyme-linked immunosorbent assay (ELISA) 
ELISA assays were performed per the manufacturer’s protocol. Briefly, 
blood was collected and centrifuged at 4,000 x g for 20 minute. Serum layer was 
removed and diluted 1:5. 96-well ELISA plates were coated with 100 µL of TNF-α 
capture antibody (2 µg/mL) and incubated overnight at 4°C. The cells were 
incubated with 300 µL of blocking solution (1% BSA, 5% sucrose, and 0.05% 
NaN3) for 1 hour at room temperature. Next, 100 µL of each sample were loaded 
to each well and incubated for 2 hour at room temperature. After washing three 
times, the plates were incubated with biotinylated anti-mouse TNF-α (250 ng/mL), 
1 µg/mL horseradish peroxidase streptavidin and substrate solution. The reaction 
was stopped by adding 50 µL of 1M H2SO4 solution. Recombinant mouse TNF-α 
was used to generate a linear standard curve. Optical density was determined with 
a SpectraMax M5 microplate reader at 450 nm (Molecular Devices). All samples 
were tested in triplicate.  
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Bioplex analysis of serum cytokine/chemokines 
Serum levels of 23 cytokine/chemokines from mice were measured using a 
Bio-Plex ProTM Mouse Cytokine 23-plex Assay (Bio-Rad, Hercules, CA, USA) on 
a Bio-Plex system following the manufacturer’s instructions. 
Quantification of atherosclerosis 
At the experimental endpoint, all mice were euthanized and the vasculature 
was perfused with cold phosphate buffer solution (PBS). The aorta from arch to 
bifurcation was fixed in 10% neutral buffered formalin. Then, it was opened 
longitudinally, pinned onto black wax plates, and stained with Sudan‐IV (Sigma‐
Aldrich, St. Louis, MO, USA) for aortic enface analysis. Aortic lesion areas were 
quantified and analyzed by ImageJ software. The aortic root was isolated and 
embedded in Optimal Cutting Temperature (OCT; Tissue-tek) compound (Sakura 
Finetek USA, Inc., Torrance, CA, USA) in a plastic mold, stored at - 20 ⁰C.  Ten‐
micrometer‐thick cryosections were cut from the proximal 1 mm of the aortic root. 
Aortic root sections were assessed for atherosclerotic plaque size with 
Hematoxylin and Eosin (H&E) staining method. To analyze the accumulation of 
macrophages in the atherosclerotic plaque, Moma-2 (Abcam, Cambridge, MA, 
USA) staining was performed. Sections were fixed in acetone for 20 minutes at 
room temperature, rinsed with PBS, followed by block in immunostain blocker 
solution, and then rinsed with PBS again. The endogenous peroxidase activity was 
blocked with 3% hydrogen peroxide. Sections were blocked for non-specific 
staining with 5% normal goat serum for 30 minutes at room temperature followed 
by incubation with the primary antibody (Moma-2, 1:400 dilution) at 4°C overnight. 
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After washing with PBS three times, the biotinylated goat anti-rabbit IgG (Vector 
Laboratories, Burlingame, CA) was used as the secondary antibody. 
Immunoreactivity was amplified using the Vectastain ABC kit (Vector 
Laboratories), and signal was enhanced by peroxidase enhancer (GeneTex, 
Irvine, CA; USA) and reacted with the substrate from AEC Chromogen/FRP 
substrate kit (GeneTex Irvine, CA; USA). Nuclei and cytoplasm were 
counterstained with haematoxylin for 1 min. Finally, sections washed with 
deionized water and air-dry before getting covered with coverslips. Macrophage 
infiltration was analyzed via microscope. Inflammatory cell infiltration was 
expressed as Moma-2 positive area. Oil red O staining was performed to detect 
lipid content in atherosclerotic plaques. Slides placed in oil red O (ORO; Sigma‐
Aldrich) working solution (0.5% in 100% propylene glycol) for 4 hours at room 
temperature. Differentiate slides in 85% aqueous propylene glycol three times for 
1 minute. Then slides rinsed with deionized water for 2 minutes. Sections were 
stained with aqueous hematoxylin (GeneTex, Irvine, CA; USA) for 20 seconds. 
Slides washed with deionized water and air-dry. Sections were covered with cover 
glasses and analyzed under a microscope. Plaque collagen content was analyzed 
using Masson's trichrome staining. Slides were fixed in Bouin’s fluid for 1 hour at 
60 °C, washed with water, and then placed in Working Weigert’s Iron Hematoxylin 
Stain for 10 minutes. Section were stained with Biebrich Scarlet-acid Fuchsin 
solution for 15 minutes and rinsed in distilled water. Next, sections were placed in 
Phosphotungstic-Phosphomolybdic Acid solution for 10 minutes, then placed in 
Aniline blue for 5 minutes followed by 1% Acetic Acid solution for 3 minutes. Finally, 
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slides were dehydrated and cleared through 95% ethanol, 100% ethanol, and 
xylenes, 2 changes each, mounted with permount, and coversliped. All images 
were recorded with a Nikon E600 Wide field Epifluorescence microscope and 
Micropublisher digital camera with Q-imaging software. Plaque size, lipid content, 
collagen percentage, and macrophage cell content were quantified by 
computerized image Pro-Plus.  
Histological analysis 
Tissue samples (Liver, lung, kidney and spleen) were fixed in 10% neutral 
buffered formalin. H&E staining and microscopy were implemented to detect 
infiltrating inflammatory cells. All tissue sections were visualized with a Nikon E 
600 microscope. 
Microarray analysis 
For microarray analysis, liver tissue was lysed with Qiazol, and total RNA 
was extracted using RNeasy Mini kit (Qiagen, Germantown, MD, USA). RNA 
quality and quantity analysis were determined using Agilent 2100 Bioanalyzer. All 
RNA samples had an RNA integrity number (RIN) of 9.2 or higher. The RNA was 
amplified and labeled with the Agilent Low Input Quick Amp labeling kit according 
to the instructions of the manufacturer. Labeled RNA was then purified using the 
Qiagen RNeasy mini kit. mRNA contained in 200 ng of total RNA was converted 
into cDNA using a poly-dT primer that also contained the T7 RNA polymerase 
promoter sequence. Subsequently, T7 RNA polymerase was added to cDNA 
samples to amplify the original mRNA molecules and to simultaneously incorporate 
cyanine-3 labeled CTP into the amplification product (cRNA). Labeled cRNA 
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molecules were purified using Qiagen’s RNeasy Mini Kit (Valencia, CA). After 
spectrophotometric assessment of dye incorporation and cRNA yield, samples 
were hybridized to Agilent whole mouse genome microarrays 8 × 60,000 using a 
gene expression hybridization kit (Agilent) according to the manufacturer’s 
recommendation. Microarray analysis was performed using an Agilent DNA 
microarray scanner system. After washes, arrays were scanned using a High 
Resolution Agilent DNA Microarray Scanner and images saved in TIFF format. A 
heat map of genes from relevant pathways identified by Ingenuity pathway analysis 
was generated using R function heatmap.2.  
Statistical analysis 
Data were presented as mean ± standard error of the mean (SEM). 
Statistical analysis was performed with Graph-Pad Prism 6.0 software (Graph-Pad 
Software Inc, San Diego, CA, USA). Statistical significance was determined by 
one-way analysis of variance (ANOVA) for multi-group comparison and Student’s 
t test for two-group comparison. Data were considered statistically significant at *P 
< 0.05, **P<0.01, and ***P<0.001. 
3.3 Results 
TTP is up-regulated in human carotid atherosclerotic lesions 
We examined the expression levels of TTP in human carotid atherosclerotic 
artery using qRT-PCR. Atherosclerotic lesion and the surrounding normal media 
from human carotid artery were dissected from patients undergoing carotid 
endarterectomy. Total RNA extraction and qRT-PCR analysis were performed to 
measure the expression of human TTP mRNA. In agreement with a previous 
  
56 
study159, we demonstrated that TTP is highly expressed in atheromatous tissue 
compared to the adjacent normal media in the carotid atherosclerotic plaques p-
value <0.05 (Figure 3.2). 
TTP deficiency in bone marrow-derived cells causes growth retardation, but 
did not affect food intake 
Five million bone marrow cells from either TTP deficient mice or WT mice 
were transplanted into lethally irradiated LDLR−/− mice. After 4 weeks recovery, the 
recipient mice were challenged with a western diet for 12 weeks, after which mice 
were sacrificed. During western diet period, mouse food intake and body weight 
were measured weekly. None of these mice showed any signs or symptoms of 
bone marrow transplant rejection. We did not observe significant differences in 
food intake between bone marrow TTP deficient mice and control mice (Figure 
3.3A). There was, however, a reduction in the mouse body weight with bone 
marrow TTP deficiency (Figure 3.3B). This reduction in body weight and cachexia 
was the most important characteristic phenotype of TTP knockout mice161. 
TTP deficiency in bone marrow-derived cells causes hematological and 
Immunological disturbance 
Previous studies showed that there is a hematological and immunological 
disturbance associated with TTP deficiency161–163. To determine the effect of bone 
marrow TTP deficiency on hematological and immunological status of TTP 
deficient bone marrow transplanted LDLR−/− mice, we performed Vetscan HMT 
analysis of peripheral blood at the experimental endpoint. The results showed an 
increase in the number of white blood cells, number and percentage of blood 
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monocytes, but these changes did not reach statistical significance, perhaps 
because of the relatively small sample number (n=5-6). There was, however, a 
significant increase in the number and percentage of neutrophils (P=0.0037, 
P=0.0336 respectively) of bone marrow TTP deficient mice compared to the 
control mice (Figure 3.4A). Total platelet number, platelet hematocrit were 
significantly increased (P=0.0107, P=0.0053 respectively) in bone marrow TTP 
deficient mice compared to the control mice (Figure 3.4B). On the other hand, we 
did not observe any differences in the red blood cell count, hemoglobin 
concentration, hematocrit, mean corpuscular volume, mean corpuscular 
hemoglobin, MCHC, and the RDWC between the two groups (Figure 3.4C). Flow 
cytometric analysis of the leukocytes population in the spleen showed a significant 
decrease in the number and percentage of CD3+/CD4+ T lymphocytes, and a 
significant increase in CD11b+/GR1+ myeloid cells, CD11b+/Ly6G+ (neutrophils), 
CD11b+/Ly6Chigh (inflammatory monocytes). Whereas, the number and 
percentage of CD19+ B lymphocytes, CD3+/CD8a+ T lymphocytes, CD4+/FoxP3+, 
CD4+/IL17+, CD11C+, F4/80+, and CD11b+/Ly6Clow were comparable between the 
two groups (Figures 3.5A & 3.5B). Even though the spleens of bone marrow TTP 
deficient mice were slightly enlarged (Figure 3.5C), the absolute cell numbers were 
comparable to those of control mice (Figure 3.5D). These results indicated that the 
bone marrow TTP deficiency causes hematological and immunological 
disturbance as previously reported in TTP knockout mice 164.  
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TTP deficiency in bone marrow-derived cells increases expression of pro-
inflammatory cytokines 
A number of pro-inflammatory cytokines produced by macrophages 
including, TNF-𝛼 and IL-6, were used to assess the ability of macrophages to 
produce cytokines163. These cytokines play a crucial role in the macrophage 
response to LPS stimulation. Peritoneal macrophages of bone marrow TTP 
deficient mice and WT mice were isolated by washing the peritoneal cavity, 
cultured and treated with LPS (50 ng/mL) for 6 hours. The expression of pro-
inflammatory cytokines TNF-α and IL-6 mRNA were measured by qRT-PCR. The 
results showed a significantly higher expression of TNF-α mRNA, p-value 0.0071 
(Figure 3.6A) and IL-6 mRNA (Figure 3.6B) in TTP deficient macrophages after 
stimulation with LPS compared to WT ones. These data indicated that TTP 
deficient macrophages had a higher ability to produce TNF-α after LPS stimulation 
and confirmed that TNF-α is one of the physiological-targets of TTP165.  
TTP deficiency in bone marrow-derived cells causes systemic and multi-
organ inflammation  
As the TTP knockout mice developed a severe inflammatory phenotype161, 
we next evaluated the inflammatory phenotype of bone marrow TTP deficient mice.  
Mouse tissues were isolated, fixed, and stained with H&E. The histological analysis 
of these mice showed a wide degree of variation, where some of them had severe 
abnormal findings, while others had a mild abnormal finding typical of whole body 
TTP knockout. The bone marrow TTP deficient mice had no difference in liver 
weight (Figure 3.6C), however, H&E staining showed a significant inflammatory 
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cell infiltration and foci of liver necrosis around the central vein (Figure 3.6D). In 
the lung of bone marrow TTP deficient mice, there was a great deal of inflammatory 
cell infiltration surrounding the vasculature, indicating the movement and migration 
of the inflammatory cells. In addition, these mice exhibit more inflammatory 
exudate in the alveolar space compared to the control group (Figure 3.6E). The 
spleen showed a loss of the normal organization with no clear demarcation 
between the red and the white pulp due to inflammatory infiltration (Figure 3.6F).   
To further define the effect of bone marrow TTP deficiency on systemic 
inflammation, we performed ELISA assays to detect serum TNF-α levels. The 
serum TNF-α concentration was increased in the bone marrow TTP deficient mice 
compared to control mice p-value 0.0004, further indicating that these mice have 
systemic inflammation (Figure 3.6G).Taken together, these data indicate that bone 
marrow TTP deficiency in LDLR−/− mice significantly increased systemic and multi-
organ inflammation. 
TTP deficiency in bone marrow-derived cells does not affect atherosclerosis 
in LDLR−/− mice 
In order to assess the effect of bone marrow TTP deficiency on 
atherosclerosis, we fed the chimeric mice a western diet for 12 weeks and 
quantified atherosclerotic lesion formation and parameters of plaque complexity. 
Even though the bone marrow TTP deficient mice have a systemic inflammation, 
the bone marrow TTP deficiency did not significantly modify the atherosclerotic 
lesion size (Figure 3.7A). Similarly, the lipid contents in the aortic root were found 
to be the same (Figure 3.7B); there was no significant difference in the 
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macrophage content (Figure 3.7C) and collagen percentage (Figure 3.7D) in bone 
marrow TTP deficient compared with the control mice. These results indicated that 
the bone marrow TTP deficiency did not result in alteration of atherosclerosis in 
LDLR−/− mice. 
TTP deficiency in bone marrow-derived cells reduces plasma lipid and 
attenuated hepatic steatosis  
Atherosclerosis is both a lipid deposition disorder and a chronic 
inflammatory disease166. Previous studies have shown that pro-inflammatory 
signaling in pre-clinical models does affect lipid metabolism167. Hyperlipidemia is 
usually associated with systemic inflammation168. Next, we investigated the effect 
of bone marrow TTP deficiency on serum lipid. Serum total cholesterol and 
triglyceride levels were measured at the indicated time points. Interestingly, after 
8 weeks of western diet the bone marrow TTP deficient mice had dramatically 
reduced serum total cholesterol and triglyceride levels compared to the control 
mice p-value 0.0001, 0.0006 respectively (Figures 3.8A and 3.8B). In agreement 
with 8 weeks western diet, at the experimental endpoint, bone marrow TTP 
deficient mice showed a significant reduction in serum cholesterol and triglyceride 
p-value 0.0009, 0.0022 respectively (Figures 3.8C and 3.8D). Fast Protein Liquid 
Chromatography (FPLC) analyses of serum lipoproteins showed the difference in 
very low-density lipoprotein (VLDL), LDL, and high-density lipoprotein (HDL) 
cholesterol peaks between bone marrow TTP deficient mice and control mice 
(Figures 2.8E and 2.8F). Interestingly, bone marrow TTP deficient mice exhibited 
significantly lower VLDL cholesterol levels, whereas no difference was observed 
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in LDL and HDL cholesterol. The liver is the most important organ involved in lipid 
metabolism169; we measured the liver lipid content of the frozen liver sections using 
the Oil-Red-O (ORO) staining and showed that hepatocytes of bone marrow TTP 
deficient mice had a dramatically reduced lipid accumulation compared to the 
levels in control mice (Figure 3.8G). Additionally, cholesterol excretion in the feces 
were significantly decreased in bone marrow TTP deficient mice p-value<0.0001 
(Figure 3.8H). We also measured the blood glucose levels and the body 
temperature at the end point. No significant differences in these parameters were 
detected between the two groups (Figures 3.8I and 3.8J). Collectively, these data 
suggest that the bone marrow TTP deficiency in atherogenic LDLR−/− mice 
dramatically reduced plasma total cholesterol levels particularly in VLDL fraction, 
and hepatic steatosis.  
TTP deficiency in bone marrow-derived cells alters expression of liver genes 
involved in inflammation and lipid metabolism 
To gain further insight into the genes related to hepatic lipid metabolism and 
inflammation in bone marrow TTP deficient mice and to further explore the 
underlying molecular mechanisms for the above observed phenotype, a 
microarray gene analysis was performed on mRNA isolated from liver of bone 
marrow TTP deficient mice and control mice. We found that bone marrow TTP 
deficiency significantly modulated 236 genes with corrected p-value cut-off:0.05 
and an absolute fold change >2.00 (Figure 3.9A). Of the 236 genes, there were 27 
genes involved in lipid metabolism, and inflammation that were significantly 
changed in bone marrow TTP deficient mice compared to mice with WT bone 
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marrow cells (Figure 3.9B). Furthermore, the lipid related genes such as sterol 
regulatory element binding transcription factor-1 (SREBF-1), which controls the 
expression of enzymes involved in fatty acid and cholesterol biosynthesis170 were 
significantly downregulated whereas the genes involved in modulating immune 
response and inflammation such as Serum Amyloid A1 (SAA1), CC chemokine 
receptor-2 (CCR2) were highly expressed in the livers of bone marrow TTP 
deficient mice.  
To confirm the gene expression patterns identified by the microarray 
analysis, qRT-PCR experiments for the mRNA expression of selected genes 
(SSA1, CCR2, and SREBF1) were performed. Indeed the expression of several 
genes from microarray data were validated by qRT-PCR. SREBF1 was 
significantly down-regulated in the liver of bone marrow TTP deficient mice; 
however, the mRNA expression of the inflammatory CCR2 and SAA1 genes were 
significantly upregulated p-value<0.05 (Figure 3.9C).  
Taken together, although we did not analyze in detail all of the differentially 
expressed genes related to lipid metabolism, our study indicated that many key 
genes related to lipid metabolism were influenced by bone marrow TTP deficiency, 
suggesting that the bone marrow TTP deficiency could change the expression of 
lipid metabolism genes particularly SREBPF1 resulting in decreased lipid 
production by the liver and subsequently reduced serum lipid, hepatic steatosis, 
and lipid excretion.  
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Effect of macrophage-specific TTP deficiency on inflammation and 
atherosclerosis development 
Macrophages play a central role in the initial step of atherosclerotic lesion 
formation171. To evaluate the contribution of macrophage TTP to atherosclerosis 
development in LDLR−/− mice, we utilized bone marrow transplantation studies to 
generate a macrophage-specific TTP deficient mouse model. We transplanted 
atherosclerosis susceptible six to eight week-old female LDLR−/− mice after lethal 
irradiation with bone marrow from either macrophage-specific TTP knockout 
(LysM-cre/TTPfl/fl, mac-TTP−/−) or control (TTPfl/fl, WT) mice. After a recovery 
period of 4 weeks on regular murine chow diet, the transplanted mice were 
challenged with a western diet for 9 weeks to induce atherosclerosis (Figure 3.1B). 
Western blot analysis and PCR were utilized to confirm that the reconstitution of 
the macrophage-specific TTP deficient bone marrow was efficient indicated by the 
lack of expression of TTP in the resident peritoneal macrophages (Figures 3.10A 
and 3.10B). During western diet period, mice body weight and food intake were 
monitored weekly. Throughout the experiment, macrophage-specific TTP deficient 
mice and control mice showed a similar food intake (Figure 3.11A) while the weight 
gain slightly reduced in macrophage-specific TTP deficient mice (Figure 3.11B). In 
addition, there were no differences in the spleen weight between the two groups 
(Figure 3.12A). Flow cytometric analysis of splenocytes showed no difference in 
leukocyte population (Figure 3.12B). To further assess the influence of 
macrophage-specific TTP deficiency on systemic inflammation, we utilized the Bio-
Plex Assays to measure the levels of cytokine/chemokines in the serum. We found 
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that macrophage-specific TTP deficiency significantly increased the plasma levels 
interleukin-12 (IL12-P40), one of the known TTP targets (Figure 3.12C). At the 
experimental endpoint, we measured serum total cholesterol (Figure 3.13A), 
triglyceride (Figure 3.13B) and lipoprotein fractions (Figure 3.13C). Interestingly, 
macrophage-specific TTP deficiency had no significant effects on serum 
cholesterol and triglyceride as well as lipoprotein fractions. After overnight fasting, 
these mice also showed similar blood glucose levels (Figure 3.13D).  
To investigate the effect of macrophage-specific TTP deficiency on 
atherosclerotic lesion development, en face aortic atherosclerotic lesion and aortic 
root lesion sizes were quantified after 9 weeks of western diet. Macrophage-
specific TTP deficiency did not significantly affect atherosclerotic lesion size as 
compared to the control mice (Figures 3.14A and 3.14B). Interestingly, ORO 
staining of the aortic root showed a significant reduction in the lipid accumulation 
in macrophage-specific TTP deficient mice p-value 0.009 (Figure 3.14C). 
Moreover, the macrophage infiltration in the atherosclerotic lesion was significantly 
reduced p-value 0.022 (Figure 3.14D). The plaque stability was also assessed by 
using trichrome staining of the aortic root section, and we found that there was no 
difference in the collagen percentage with macrophage-specific TTP deficiency 
(Figure 3.14E).  
3.4 Discussion 
TTP is a member of CCCH tandem zinc finger proteins family. It binds via 
its tandem zinc finger domain to AU rich elements (AREs) found in 3’ UTR of the 
target mRNAs such as that of TNF-α, resulting in deadenylation and destabilization 
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of the target mRNAs164,172. TTP has been demonstrated to play a significant role 
in controlling inflammation in the vascular endothelial cells159.  
Previous studies demonstrated that TTP deficiency resulted in development 
of a complex syndrome of myeloid hyperplasia with cachexia, skin lesions, arthritis, 
conjunctivitis, kidney lesions, and that treatment with TNF-α antibodies161 or 
interbreeding the mice with TNF-R deficient mice 173 could attenuate development 
of above inflammatory phenotype in the TTP deficient mice. Transplantation of 
TTP deficient hematopoietic cells reproduces the whole body TTP knockout 
inflammatory syndrome in RAG-2 deficient mice, indicating that hematopoietic 
cells contribute dominantly to the phenotype153. However, the effects of bone 
marrow TTP deficiency on atherosclerosis have not been studied. In our study, we 
transplanted bone marrow cells from either TTP knockout mice or WT mice into 
LDLR−/− mice, and we wanted to test if the bone marrow transplantation of TTP 
deficient cells could transfer the inflammatory phenotype of TTP knockout mice 
into recipient atherogenic LDLR−/− mice and to examine the impact of bone marrow 
TTP deficiency on atherosclerosis development. TTP has anti-inflammatory 
properties, and inflammation plays a significant role in the development of 
atherosclerosis174; therefore, we expected that the bone marrow TTP deficiency 
would increase inflammation and lead to increased atherosclerosis in 
hyperlipidemic LDLR−/− mice. First we studied the inflammatory phenotype in bone 
marrow TTP deficient mice and found that TTP deficient bone marrow 
transplantation into LDLR−/− mice resulted in all aspects of TTP knockout syndrome 
including: growth retardation, systemic and multi-organ inflammation, suggesting 
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that hematopoietic progenitors are responsible for the development of the 
inflammatory syndrome. We then aimed to determine whether bone marrow TTP 
deficiency affects atherosclerosis development. A comparable lesion size in the 
aortic root was observed between bone marrow TTP deficient mice and control 
mice. Plaque composition analysis showed no effects of bone marrow TTP 
deficiency on the lipid content or macrophage content either, as well as amount of 
collagen. Then we evaluated the effect of bone marrow TTP deficiency on lipid 
profile and found that these mice had a significant reduction in plasma lipid and 
hepatic steatosis. Increased inflammation and reduced plasma lipid might thus 
counteract each other leaving atherosclerosis development unchanged in bone 
marrow TTP deficient mice compared to bone marrow WT mice. Previous studies 
demonstrated the inflammatory phenotype of TTP knockout mice, and that 
transplantation of TTP deficient bone marrow cells into RAG2 deficient mice could 
transfer all aspects of TTP deficiency syndrome. We, for the first time, show that 
bone marrow TTP deficiency significantly increased inflammation, reduced plasma 
lipid, and attenuated hepatic steatosis, but did not affect western diet-induced 
atherosclerotic lesion development in LDLR−/− mice. Bone marrow TTP deficient 
mice had lower body weight than control mice; these mice also displayed 
hematopoietic abnormalities including slightly elevated white blood cell count, 
increased absolute number and percentage of neutrophils, increased absolute 
number and percentage of blood monocytes. The peripheral red blood cell count, 
hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin 
were not different between the two groups. However, the platelet count, and 
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platelet hematocrit were significantly increased (P=0.0107, P=0.0054 respectively) 
in bone marrow TTP deficient mice. Flow cytometric analysis of the leukocyte 
population in the spleen revealed that CD3+/CD4+ T cell numbers and percentage 
decreased significantly with bone marrow TTP deficiency, whereas the number 
and percentage of neutrophils and inflammatory monocytes were increased 
significantly in bone marrow TTP deficient mice compared to the control mice. No 
difference was observed in the B lymphocytes between the two groups. In addition, 
the isolated peritoneal macrophages were cultured and treated with LPS (TLR4 
ligand), and shown to have a significantly higher expression of pro-inflammatory 
cytokines, TNF-α and IL-6, indicating that TTP deficiency increased 
responsiveness of macrophages to LPS stimulation. The most striking observed 
feature of TTP deficiency is the diffuse multi-organ inflammation161,162. Our data 
demonstrated that the bone marrow TTP deficiency results in inflammatory cell 
infiltration in multiple organs including liver and lung. The spleen weight of bone 
marrow TTP deficient mice was slightly enlarged compared to the control mice. In 
addition, microscopically there is a disturbed morphology of the spleen due to a 
large inflammatory cell infiltration in bone marrow TTP deficient mice. Those mice 
also had increased plasma TNF-α levels. We expected that, with the increase in 
inflammation caused by bone marrow TTP deficiency, more severe 
atherosclerosis would develop in these mice. However, bone marrow TTP 
deficiency did not increase atherosclerosis in LDLR−/− mice after 12 weeks of 
western diet feeding. Interestingly, the plasma total cholesterol and triglyceride 
levels, especially those in the VLDL fractions were significantly reduced in bone 
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marrow TTP deficient mice. Additionally, these mice showed significantly 
decreased hepatic lipid accumulation (hepatic steatosis) compared to bone 
marrow WT mice.  
 To gain further insight into the genes related to lipid metabolism and 
inflammation in the bone marrow TTP deficient mice, and to understand the 
underlying molecular mechanism by which bone marrow TTP deficiency reduces 
liver lipid production, we performed a microarray analysis to compare the liver gene 
expression patterns of these mice. We found that there were 236 genes 
significantly changed with bone marrow TTP deficiency; among these there were 
27 genes involved in lipid metabolism and inflammation that were significantly up 
or down regulated with bone marrow TTP deficiency. Those down-regulated genes 
tend to regulate cholesterol and fatty acid metabolism such as SREBF1 and 
ABCG8, whereas up-regulated genes were involved in inflammation such as 
CCR2, SAA1, and Calgranulin A (S100A8) a biomarker for chronic inflammatory 
diseases175. SREBF-1, a key transcription factor regulating lipogenic enzymes170. 
To further dissect the role of macrophage TTP in atherosclerosis 
development, we transplanted the bone marrow cells from macrophage-specific 
TTP knockout mice or WT mice to LDLR−/− mice. After 4 weeks of hematopoietic 
reconstitution followed by 9 weeks of western diet, the serum concentration of IL-
12P(40) was the only cytokine significantly increased in macrophage-specific TTP 
deficient mice than the control. Furthermore, no significant change in serum 
cholesterol and triglyceride levels were observed with macrophage-specific TTP 
deficiency. Finally, the atherosclerotic lesion size in LDLR−/− mice was unchanged. 
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However, macrophage-specific TTP deficiency resulted in significant changes in 
lesion composition during the initial stages of plaque development. This occurred 
through reduction in macrophage infiltration, and lipid content. Overall, our data 
demonstrated that loss of macrophage-specific TTP expression in LDLR−/− mice 
results in unchanged atherosclerosis indicating that TTP expression in 
macrophages does not play an important role in atherogenesis. 
In conclusion, our study provides evidence that bone marrow TTP 
deficiency in LDLR−/− mice results in significantly increased inflammation and 
attenuated hyperlipidemia. The increased systemic inflammation and reduced 
serum lipid levels in bone marrow TTP deficient mice offset each other and resulted 
in no significant change in the atherosclerosis development in mice. Although it is 
unknown if TTP directly acts on lipoprotein metabolism related genes, it is 
intriguing to hypothesize that targeting certain components of immune system and 
inflammation may have unexpected effects on hepatic lipoprotein metabolism. This 
aspect is a subject for further investigation. In addition, our results demonstrate 
that macrophage-specific TTP deficiency had less robust effects than whole bone 
marrow cell TTP deficiency on inflammation and serum lipid, suggesting TTP 
expression in other bone marrow-derived cells contributes more to inflammation 
and lipoprotein metabolism.  
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Table 3. 1 Primers that were used for qRT-PCR in this study 
 
Primers Forward (5’  3’) Reverse (5’  3’) 
m18s CGCGGTTCTATTTTGTTGGT AGTCGGCATCGTTTATGGTC 
hTTP TACGAGAGCCTCCAGTCGAT GCGAAGTAGGTGAGGGTGA
C 
mTNF-α CGT CAG CCG ATT TGC TAT 
CT 
CGGACTCCGCAAAGTCTAAG 
mIL6 AGTTGCCTTCTTGGGACTGA TCCACGATTTCCCAGAGAAC 
mSREBF
1 
GCCCACAATGCCATTGAGA GCAAGAAGCGGATGTAGTCG
AT 
mCCR2 ATTCTCCACACCCTGTTTCG GATTCCTGGAAGGTGGTCA 
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Figure 3. 1 In vivo experimental design, mouse model and bone marrow 
transplantation used for assessment of atherosclerosis 
(A) six to eight week-old female LDLR−/− mice were provided with autoclaved 
antibiotics water containing neomycin (100 mg/L) and polymyxin B sulphate 
(60.000 U/L) one week before and two weeks after bone marrow transplantation. 
Mice received total body irradiation. Bone marrow cells were isolated from TTP 
knockout mice or control mice and 5 x 106 cells injected into LDLR−/− mouse in the 
retro-orbital plexus. Four weeks after the BMT, mice were fed a western diet for a 
period of 12 weeks, then the mice were sacrificed for atherosclerosis analysis. (B) 
six to eight week-old female LDLR−/− mice were provided with autoclaved 
antibiotics water one week before and two weeks after BMT. Mice received total 
body irradiation. Bone marrow cells were isolated from macrophage-specific TTP 
deficient mice or control mice and 5 x 106 cells injected into LDLR−/− mouse. Four 
weeks after BMT, mice were fed a western diet for 9 weeks, then the mice were 
sacrificed for atherosclerosis analysis. 
 
 
 
  
72 
 
N
or
m
al
 m
ed
ia
A
th
er
om
a
0
5
10
15
20
25 *

c
t 
(h
T
T
P
)
 
 
Figure 3. 2 TTP expression is increased in human carotid atherosclerotic 
lesions 
TTP expression in human carotid artery was analyzed by qRT-PCR. Expression 
levels of TTP were significantly increased in carotid atherosclerotic lesions 
compared to those in the non-lesion carotid medial tissue. Results were 
represented as ΔCt values after being normalized to the expression of 18s rRNA. 
ΔCt is the difference in threshold cycle between the gene of interest and the 
housekeeping gene (18s). Each line connects data from a same patient. (*p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
  
73 
 
  
 
Figure 3. 3 Bone marrow TTP deficiency causes growth retardation, but did 
not affect food intake  
Six to eight week-old female LDLR−/− mice were transplanted with TTP knockout or 
WT bone marrow cells. Four weeks after BMT, mice were fed a western diet for 12 
weeks. (A) Food intake and (B) body weight were monitored weekly. The average 
daily intake of western diet per mouse was calculated. Data are presented as mean 
± SEM. 
  
74 
 
Figure 3. 4 Bone marrow TTP deficiency causes hematological disturbance  
VetScan hematology analyzer was utilized to measure the following parameters: 
(A) white blood cell and white blood cells differential counts in peripheral blood at 
the experimental endpoint. (B) Total platelet number, mean platelet volume, 
platelet distribution width (PDWc), and the platelet hematocrit. (C) Red blood cell 
(RBC) number, hemoglobin (HGB) concentration and hematocrit (HCT), mean 
corpuscular volume, mean corpuscular hemoglobin concentration (MCHC), red 
cell distribution width (RDWc). All data were presented as the mean ± SEM.  
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Figure 3. 5 Bone marrow TTP deficiency causes immunological disturbance 
Spleens from bone marrow TTP deficient mice and bone marrow WT mice were 
collected at experimental end point. A single cell suspension was made, and the 
cells were stained with different antibodies to detect different mouse leukocyte 
populations by flow cytometry. (A) Absolute number and (B) percentage of 
leukocytes in the spleen. (C) Spleen weight of LDLR−/− mice that received WT or 
TTP deficient bone marrow cells. (D) Total spleen cell numbers of LDLR−/− mice 
that received WT or TTP deficient bone marrow cells. (*P<0.05; **P<0.01). 
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Figure 3. 6 TTP deficiency increased macrophage responses to LPS 
stimulation, and bone marrow TTP deficiency resulted in extensive 
inflammatory tissue damage and systemic inflammation  
Residential peritoneal macrophages were obtained from mice at the experimental 
endpoint. The cells were treated with LPS (50 ng/mL) for 6 h. Total mRNA was 
extracted for qRT-PCR measurement of the inflammatory cytokine expression (A) 
TNF-α, (B) IL-6 (N=3 for each group). (C) Liver weight of LDLR−/− mice received 
WT or TTP deficient bone marrow cells. Representative photomicrographs 
showing H&E staining in the (D) liver (20x), (E) lung (20x), and (F) spleen (10x) in 
wild-type recipient mice (right panels) and TTP deficiency recipient mice (left 
panels). (G) Serum TNF-α concentrations of bone marrow TTP deficient mice and 
control mice were determined by ELISA. Data were analyzed by Student’s t test. 
*p < 0.05; **p < 0.01; ***p < 0.001. 
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Figure 3. 7 Bone marrow TTP deficiency had no impact on atherosclerosis 
after 12 weeks of western diet in LDLR−/− mice  
To induce atherosclerosis, bone marrow transplanted LDLR−/− mice were fed a 
western diet for 12 weeks. The aortic roots were embedded in OCT and frozen at 
-20 °C. For analysis of atherosclerosis, 10 µm thick sections were collected. (A) 
The aortic root lesion area of the frozen sections was detected by H&E staining 
and quantified by Image-ProPlus 6.0. The representative images and quantitative 
analysis are shown. (B) Lipid contents in the aortic root lesions were determined 
by ORO staining. The representative images and quantitative analysis are shown. 
(C) The areas of macrophages in the aortic root lesions were determined by 
immunostaining for MOMA-2 (a macrophage marker). The representative images 
and quantitative analysis are shown. (D) Collagen content in the aortic root lesions 
was determined by masson’s trichrome staining. The representative images and 
quantitative analysis are shown. 
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Figure 3. 8 Bone marrow TTP deficiency markedly reduced serum lipid 
levels and attenuated hepatic steatosis 
Mouse serum cholesterol (A) and triglyceride (B) levels were measured after 8 
weeks of western diet. Mouse serum cholesterol (C) and triglyceride (D) levels 
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were measured at the experimental end point. (E, F) Pooled serum samples from 
mice at the experimental endpoint were analyzed for the lipoprotein profile using 
FPLC analysis. Cholesterol or triglyceride content in each fraction was determined. 
Data represent the mean ±SEM. (G) Representative images and quantification of 
ORO stained liver sections. (H) Fecal cholesterol excretion was detected at the 
experimental end point. (I) Fasting blood glucose levels of mice at the experimental 
end point were measured. (J) Body temperatures at the experimental end point 
were measured. *p < 0.05; **p < 0.01; ***p < 0.001. 
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Figure 3. 9 Bone marrow TTP deficiency alters expression of liver genes 
involved in inflammation and lipid metabolism  
(A) Heat map showing the expression of 236 genes significantly changed in the 
liver of bone marrow TTP deficient mice compared to control mice (2.00 fold 
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change cutoff). (B) Heat map of 27 genes involved in inflammation and lipid 
metabolism significantly changed with bone marrow TTP deficiency. Color coding 
indicates increased gene expression in red, and decreased expression in green. 
The columns and rows in the heat maps represent samples and genes, 
respectively. (C) Quantitative real-time RT-PCR analysis of liver mRNA was used 
to verify the results of selected genes from microarray data.  
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Figure 3. 10 Efficiency of macrophage-specific TTP deficiency in the bone 
marrow transplantation model 
Thioglycollate-elicited peritoneal macrophages were lysed in Trizol reagent for 
mRNA isolation and PCR analysis or RIPA buffer for protein isolation and western 
blot analysis. Western blot and PCR were utilized to detect TTP protein (A) and 
TTP mRNA (B) expression. 
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Figure 3. 11 macrophage-specific TTP deficiency did not affect mouse food 
intake, but reduced body weight  
LDLR−/− mice were transplanted with WT or macrophage-specific TTP deficient 
bone marrow cells. Four weeks after bone marrow transplantation, mice were fed 
a western diet for 9 weeks. (A) Food intake and (B) body weight were monitored 
weekly. The average daily intake of western diet per mouse was calculated. Data 
are presented as mean ± SEM. 
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Figure 3. 12 Effect of macrophage-specific TTP deficiency on inflammation 
 (A) Spleen weight of LDLR−/− mice that received WT or macrophage-specific TTP 
deficient bone marrow cells at the experimental endpoint. (B) Flow cytometry 
analysis of leukocyte population in the spleen. Percentage of each subset of cells 
were shown. Data are represented as the mean ± SEM. (C) Serum levels of 23 
chemokine/cytokines were measured by Bio-Plex ProTM Mouse Cytokine 23-plex 
Assay. Data are presented as the mean ± SEM. *P<0.05. 
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Figure 3. 13 Effect of macrophage-specific TTP deficiency on plasma lipid 
levels and lipoprotein profile  
LDLR−/− mice reconstituted with WT or macrophage-specific TTP deficient bone 
marrow cells were fed a western diet for 9 weeks. Blood samples were drawn after 
overnight fasting. The concentrations of cholesterol (A) and triglycerides (B) in 
serum were determined using enzymatic colorimetric assays. (C) Plasma 
lipoproteins profile was determined by FPLC analysis. Fractions represent VLDL, 
LDL, and HDL, respectively. (D) Fast blood glucose levels after were determined. 
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Figure 3. 14 Effect of macrophage-specific TTP deficiency on atherosclerosis 
(A) Representative image of the aorta stained with Sudan IV and quantification of 
the surface area occupied by the lesions. (B) Representative images and 
quantitative analysis of atherosclerotic lesion size in the aortic root of WT and 
macrophage-specific TTP deficient mice. (C) Representative images and 
quantitative analysis of ORO stained aortic root. **p<0.001. (D) Representative 
images and quantitative analysis of MOMA2 stained area in the aortic root. 
*P<0.05 (E) Representative images and quantitative analysis of collagen content 
in the aortic root.
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Chapter IV 
The effect of macrophage-specific GP-96 deficiency on inflammation and 
atherosclerosis development 
4.1 Background 
Glycoprotein-96 (GP-96), also known as glucose regulated protein-94 
(GRP-94), endoplasmin, or 99-kDa endoplasmic reticulum protein (ERp99), is an 
endoplasmic reticulum (ER)-resident chaperone/stress protein176.  GP-96 is 
expressed in various cell types, and its expression can be upregulated by 
accumulation of misfolded proteins and other stress conditions that leads to 
disturbance in the ER functions177,178. Initially, GP-96 was discovered as a protein 
strongly induced by glucose starvation in hamster fibroblasts as a major 
endoplasmic reticulum calcium-binding protein179. Recently, the role of GP-96 in 
innate immunity, inflammation and oncogenesis started to be appreciated180,181.  
GP-96 plays a major role in maintaining protein homeostasis by catalyzes 
the folding of the newly synthesized proteins such as Toll like receptors (TLRs), 
Wnt co-receptor LRP6, insulin-like growth factors, immunoglobulins (Ig), and some 
integrins180,182,183. Global deletion of GP-96 is embryonically lethal and not 
compatible with life because it is responsible for chaperoning of multiple proteins 
induction and muscle development183. 
To study the effect of GP-96 on TLR expression and the immune function, 
myeloid-specific GP96 deficient mice were generated and extensively studied. 
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LysM-Cre/ GP-96fl/fl is highly macrophage selective, without affecting other cell 
populations180. Macrophage-specific GP-96 deficient mice have normal 
hematopoiesis and normal immune cell numbers (e.g. macrophages, dendritic 
cells, and leukocytes). In-vivo studies revealed that macrophage-specific GP-96 
deficient mice had a significant decrease in the production of pro-inflammatory 
cytokines and were relatively resistant to endotoxic shock induced by LPS injection 
(TLR4 ligand). GP-96 is capable of activating the TLR signaling pathways 
determined by the ability to induce pro-inflammatory cytokine/chemokines. In vitro 
studies demonstrated that macrophages isolated from macrophage-specific GP-
96 deficient mice significantly reduced production of pro-inflammatory cytokines 
such as TNF-α upon stimulation with TLRs agonist, indicating the role of GP-96 in 
TLR expression180,182.  
Toll like receptors (TLRs) are the best characterized pattern recognition 
receptors (PRRs).They are prominently involved in the first line defense against 
infection by recognizing conserved motifs expressed by pathogens called 
pathogen-associated molecular patterns (PAMPs) and thereby initiate the innate 
immune response. TLRs are highly expressed by a number of immune cells such 
as macrophages and dendritic cells (DCs) as well as non-immune cells such as 
epithelial cells and fibroblasts184,185. To date, thirteen functional TLRs have been 
identified in mouse that are either expressed on the cell surface and recognize 
microbial membrane components (e.g. TLR1, TLR2, TLR4, TLR5, TLR6, TLR11, 
and TLR12) or are associated with intracellular vesicles and recognizes nucleic 
acids (e.g. TLR3, TLR7, TLR8, TLR9 and TLR13)186. The role of TLRs in 
  
91 
atherosclerosis development is still controversial. Recent evidence suggests that 
TLRs have both protective and detrimental roles in atherosclerosis. Previous study 
suggests a detrimental role for TLR signaling in atherosclerosis, demonstrating 
that the whole-body deficiency of MyD88 reduced both atherosclerotic lesion 
development and macrophage accumulation in apoE−/− mice. This study was 
confirmed and followed by another study demonstrating that whole body 
TLR2/TLR4 deficiency in murine models of atherosclerosis results in a significant 
reduction in atherosclerotic lesion formation via inhibition of lipid deposition, 
inflammatory cell recruitment and activation187,188. Other studies showed the 
athero-protective functions of TLRs in atherosclerosis189,190. 
Blocking TLRs signaling in the macrophage is considered to be a promising 
strategy to halt the inflammation and attenuate atherosclerosis. While GP-96 has 
been shown to modulate both the innate and adaptive immune systems by 
controlling most TLRs, the role of GP-96 in atherosclerosis has not been 
investigated. To address the role of GP-96 in immune responses during 
atherogenesis, we transplanted macrophage-specific GP-96 deficient or WT bone 
marrow cells into LDLR−/− mice and fed them a western diet for 9 weeks. Recipient 
mice reconstituted with macrophage-specific GP-96 deficient bone marrow cells 
had no significant difference in inflammation compared with control mice 
transplanted with WT bone marrow cells. In addition, macrophage-specific GP-96 
deficient mice displayed a comparable serum lipid, resulting in unchanged 
atherosclerosis in LDLR−/− mice. 
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4.2 Material and Methods 
Mice  
Six to eight week-old female LDLR−/− mice (C57BL/6J background) were 
purchased from the Jackson Laboratory (Bar Harbor, MA, USA). Mice were 
maintained in pathogen-free conditions at the University of South Carolina Animal 
Research Facility according to National Institutes of Health (NIH) guidelines. All 
animal experiments were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of South Carolina. 
Bone Marrow Transplantation (BMT) and atherosclerosis induction   
BMT was performed as previously described in chapter 2. Briefly, six to 
eight week-old female LDLR−/− mice were maintained on antibiotic water 
containing 100 mg/L neomycin and 10 mg/L polymyxin B, one week before and 2 
weeks after BMT. Six hours before BMT, recipient mice were lethally irradiated 
(900 rad) using a cesium gamma source. Bone marrow cells were harvested by 
flushing both femurs and tibias from WT or macrophage-specific GP-96 deficient 
mice (kindly provided by Dr. Zihai Li at the Medical University of South Carolina) 
with sterile RPMI-1640 medium (Invitrogen Life Technologies, Grand Island, NY, 
USA) containing 2% fetal bovine serum (Invitrogen, Grand Island, NY, USA) and 
heparin (5 units/mL, Sigma, St. Louis, MO, USA). The cell suspension was 
centrifuged for 5 minutes at 300 x g and re-suspended in ice cold phosphate buffer 
saline (PBS). Five million bone marrow cells from donor mice were injected into 
the retro-orbital venous plexus of the recipient irradiated LDLR−/− mice. After 4 
weeks recovery, mice were fed a western diet containing 21% (w/v) anhydrous 
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milkfat, 34% (w/v) sucrose, and a total of 0.2% (w/v) cholesterol (Harlan 
laboratories; Indianapolis, IN, USA) for a duration of 9 weeks, after which mice 
were sacrificed (Figure 4.1). During a western diet period, mouse food intake and 
body weight were measured weekly throughout the study.  
Peritoneal macrophage isolation and culture 
Mice were injected i.p. with 3 mL of 3% (w/v) thioglycolate solution (BD 
Biosciences Clontech; Palo Alto CA, USA). Three days later, mice were 
anesthetized with isoflurane, and macrophages were obtained by washing 
peritoneal cavity with 10 mL of cold PBS twice. The cells were then re-suspended 
in high-glucose Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Grand 
Island, NY, USA) supplemented with 10% fetal bovine serum (FBS), a combination 
of penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO, USA), and 50 μM of β-
mercaptoethanol. After incubation for 2 hours at 37°C, non-adherent cells were 
washed away with PBS, and adherent cells were cultured overnight in serum free 
DMEM. Then macrophages were treated with DMEM containing LPS (50 ng/mL, 
Sigma-Aldrich, St. Louis, MO, USA) for 6 hours. Next, cells were washed with 
Dulbecco’s phosphate-buffered saline (DPBS) twice before being lysed for total 
RNA or protein extraction. 
Assessment of successful bone marrow reconstitution 
The success of bone marrow reconstitution of LDLR−/− mice was 
determined at the experiment endpoint. Isolated peritoneal macrophages were 
lysed in Trizol reagent for PCR analysis or in RIPA buffer for western blot analysis. 
GP-96 mRNA and protein levels were detected.  
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RNA extraction, cDNA synthesis, and quantitative real-time PCR 
Total RNA was extracted using TRIzol reagent (Life Technologies, Grand 
Island, NY, USA) according to the standard protocol. One microgram of RNA of 
each sample was reverse transcribed into cDNA using iScript™ cDNA Synthesis 
Kit (Bio-Rad Life Science, Hercules, CA). qRT- PCR was performed using iQ™ 
SYBR® Green Supermix (Bio-Rad, Hercules, CA, USA) according to the 
manufacturers’ instructions. The relative amount of target mRNA was determined 
using the comparative threshold (Ct) method by normalizing target mRNA Ct 
values to those of 18S RNA. PCR thermal cycling conditions were 3 min at 95°C, 
and 40 cycles of 15 s at 95°C and 58 s at 60°C. Samples were run in triplicate. 
The primers used for qRT-PCR are shown in table 4.1. 
Western blot analysis 
After 9 weeks of western diet, peritoneal macrophages were isolated, 
cultured, and incubated in the absence or presence of LPS (50 ng/mL) for 24 
hours. To obtain the total cell lysates, the attached cells were incubated and lysed 
for 30 min on ice in RIPA buffer (PierceTM, Rockford, IL, USA) supplemented with 
protease inhibitor cocktail and phosphatase inhibitors (Sigma-Aldrich, St. Louis, 
MO, USA). Equal amounts of total cell proteins (30 µg) were separated in 4-20 % 
SDS-PAGE pre-cast gels (Bio-Rad, Hercules, CA, USA) for electrophoresis and 
transferred onto Nitrocellulose membranes (Millipore Corp., Bedford, MA, USA). 
After blocking with 5% non-fat dry milk, primary antibodies and HRP-conjugated 
secondary antibodies were used to detect target proteins. Signal was detected 
using Pierce ECL Western Blotting Substrate (PierceTM, Rockford, IL, USA). For 
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stripping, membranes were submerged for 30 minutes at 55 – 60°C in a buffer 
containing 100 mM 2-mercaptoethanol, 2% SDS and 62.5 mM Tris-HCl, pH 6.7, 
and washed three times with PBST. 
Serum lipid and lipoprotein distribution analysis  
After an overnight fast, ~ 500 µL blood was collected from each mouse by 
retro-orbital venous plexus puncture and centrifuged at 4,000 x g for 20 min. Serum 
total cholesterol and triglyceride levels were determined by enzymatic colorimetric 
assays with Cholesterol Reagent and Triglycerides GPO reagent kits (Raichem, 
San Diego, CA, USA), and analyzed by SoftMax Pro5 software (Molecular 
Devices, Sunnyvale CA, USA). Serum lipoproteins were determined using a fast-
performance liquid chromatography (FPLC) system (AKTA purifier, GE Healthcare 
Biosciences, Pittsburgh, PA, USA) equipped with a Superose 6 10/300 GL column 
(GE Healthcare). Pooled mouse plasma (100 µL) was loaded into the column, and 
eluted at a constant flow rate of 0.5 mL/min with 1 mM sodium EDTA and 0.15 M 
NaCI. Fractions of 0.5 mL were collected and cholesterol concentration from each 
fraction was measured. 
Blood glucose measurement  
OneTouch Ultra Blood Glucose Monitoring System (LifeScan, Inc., Milpitas, 
CA, USA) was used to measure the blood glucose concentration following the 
manufacturer’s instructions. 
Flow cytometry analysis  
After 9 weeks of western diet feeding, the mice (not thioglycollate 
stimulated) were sacrificed. Spleens were obtained and smashed in 10 mL RPMI-
  
96 
1640 medium supplemented with 10% FBS using Stomacher® 80 Biomaster 
(Seward Laboratory Systems Inc., Port St. Lucie, FL, USA). Red blood cells in 
spleen samples were lysed using red blood cell lysing buffer (Sigma-Aldrich, St. 
Louis, MO, USA). To obtain single cell suspensions, tissue were passed through 
a 70 µM cell strainer (Life Sciences, Tewksbury, MA, USA). Cells were fixed, 
permeabilized, and stained for 30 min on ice in dark using the following antibodies: 
PE-anti-CD3, FITC-anti-CD4, FITC-anti-CD8a, FITC-anti-CD19, FITC-anti-
CD11c, PE-anti-CD11b, FITC-anti-Ly6C, FITC-anti-Ly6G, and FITC- anti -F4/80 
mAb (eBioscienceTM, Invitrogen) in staining buffer. Stained cells were acquired on 
a Cytomics FC 500 flow cytometer and further analyzed with CXP software version 
2.2 (Beckman Coulter, Brea, CA, USA). Data were collected for 10,000 live events 
per sample.  
Bioplex analysis of serum cytokine/chemokines 
Serum levels of 23 cytokine/chemokines from mice were measured using a 
Bio-Plex ProTM Mouse Cytokine 23-plex Assay (Bio-Rad, Hercules, CA, USA) on 
a Bio-Plex system following the manufacturer’s instructions. 
Atherosclerosis analysis 
To induce atherosclerosis, mice were fed a western diet for 9 weeks. At the 
experimental endpoint, mice were sacrificed and their vasculature perfused with 
10 mL of cold PBS via cardiac puncture to remove blood contamination from 
vascular tissue. Hearts and aortas were dissected, and the aortic root was isolated 
and embedded in OCT compound in a plastic mold, frozen at - 20 ⁰C, and cut into 
10 µm sections. For the aortic enface assay, aortas were fixed in 10% neutral 
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buffered formalin, cleaned, opened longitudinally, pinned onto black wax plates, 
and stained with Sudan‐IV (Sigma‐Aldrich, St. Louis, MO, USA). The lesion areas 
were quantified and analyzed by ImageJ software. Atherosclerotic lesion areas in 
the aortic root were visualized with H&E staining, and lipid-deposition with ORO 
staining and quantified by Image-Pro Plus 6.0 as previously described in chapter 
3. For macrophage analysis, rat anti-mouse MOMA2 (Abcam, Cambridge, MA, 
USA) was used for immunostaining on serial sections of the aortic root, and 
biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA) was 
used as the secondary antibody. Vectastain ABC kit (Vector Laboratories, 
Burlingame, CA, USA) was used to amplify the immunoreactivity, and signal was 
enhanced by Peroxidase Enhancer (GeneTex, Irvine, CA, USA), and finally 
reacted with the substrate from AEC Chromogen/FRP substrate kit (GeneTex, 
Irvine, CA, USA). Masson’s trichrome staining was used as previously described 
in chapter 3 to detect collagen content in the aortic root sections. All images were 
recorded with a Nikon E600 Wide field Epifluorescence microscope and 
Micropublisher digital camera with Q-imaging software. Data were quantified by 
computerized image Pro-Plus. 
Statistical analyses 
Data were presented as mean ± SEM. Statistical significance was 
calculated by Student’s t test for two-group comparison or one-way analysis of 
variance (ANOVA) for multi-group comparison using the Graph-Pad Prism 
statistical program (Graph-Pad Software, Inc., San Diego, CA). p<0.05 was 
considered statistically significant. 
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4.3 Results 
Efficiency of macrophage-specific GP-96 knockout  
After bone marrow transplantation and 9 weeks of western diet, PCR and 
western blot analysis were used to confirm the efficiency of macrophage-specific 
GP-96 knockout. Macrophage-specific GP-96 deficient mice exhibit a significant 
loss (but not complete absence) of GP-96 in peritoneal and splenic macrophages, 
while the GP-96 expression was unaffected in splenic B-cells and T-cells (Figures 
4.2A, 4.2B and 4.2C).  
As GP-96 is the master chaperone for multiple TLRs, we next detected the 
expression of TLR4 in peritoneal macrophages using western blot analysis. 
Macrophage-specific GP-96 deficient macrophages displayed a significant 
decrease in TLR4 expression (Figure 4.2D).  
Macrophage-specific GP-96 deficiency does not affect mouse food intake 
and body weight 
We transplanted five million bone marrow cells from either WT (control) or 
macrophage-specific GP-96 deficient mice to lethally irradiated LDLR−/− mice. Four 
weeks following the bone marrow transplantation, the recipients LDLR−/− mice 
were fed a western diet for 9 weeks to induce atherosclerosis. During the western 
diet feeding period, we measured the food intake and body weight weekly. 
Throughout the experiment, macrophage-specific GP-96 deficient mice and control 
mice showed no difference in food intake (Figure 4.3A) and body weight (Figure 
4.3B). 
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Macrophage GP96 is not required for the inflammatory response during 
atherosclerosis progression 
The effect of macrophage-specific GP96 deficiency on inflammation has 
been examined. Initially, the spleen weight was measured at the experimental 
endpoint. No significant differences were observed between the two groups 
(Figure 4.4A). Next, flow cytometric analysis of the splenocytes was performed to 
determine the leukocyte population in the spleen. Several different leukocyte 
populations were investigated and the results showed that there were no 
significant differences in the percentage of leukocyte populations in the spleen 
between macrophage-specific GP96 deficient mice and control mice (Figure 4.4B).  
To obtain further insight into the role of macrophage-specific GP96 
deficiency in systemic inflammation during atherosclerosis, we measured serum 
levels of cytokine/chemokines using Bio-plex assays. We found that there was no 
difference in these cytokine/chemokines between the two groups (Figure 4.4C). 
This indicates that macrophage-specific GP96 deficiency did not significantly affect 
inflammation in LDLR−/− mice. 
Macrophage-specific GP96 deficiency does not affect serum lipid levels 
After 9 weeks of western diet feeding, serum cholesterol and triglyceride 
levels were measured and there were no significant differences between the 
macrophage-specific GP-96 deficient group and the control group (Figures 4.5A 
and 4.5B). Analysis of the plasma lipoprotein profile by FPLC showed no significant 
difference in VLDL, LDL and HDL cholesterol fractions in macrophage-specific GP-
96 deficient mice compared to the control mice (Figure 4.5C). In addition, blood 
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glucose levels were comparable between the two groups (Figure 4.5D). These 
findings indicated that macrophage-specific GP-96 deficiency did not affect serum 
lipid levels.  
Macrophage-specific GP-96 deficiency does not influence progression of 
atherosclerosis  
Bone marrow recipient mice were sacrificed and the extent of early stages 
of atherosclerosis in the aorta and aortic root were analyzed. A comparable lesion 
size in the aorta and aortic root was observed between macrophage-specific GP-
96 deficient mice and control mice (Figure 4.6A and 4.6B). Moreover, all 
parameters of plaque complexity including lipid accumulation (Figure 4.6C), 
macrophage infiltration (Figure 4.6D) as well as collagen content (Figure 4.6E) in 
the atherosclerotic lesions were similar between the two groups of mice. This 
indicates that macrophage GP-96 is dispensable for both inflammation and 
atherosclerosis development in LDLR−/− mice. 
4.4 Discussion 
GP-96 has been implicated in antigen presentation and activation of the 
innate and adaptive immunity191. GP-96 participates in the folding and assembly 
of many secretory and membrane proteins, and is essential for the cell-surface 
expression of TLRs including TLR2 and TLR4180,192. Given the fact that GP-96 
deficiency is associated with loss of multiple TLRs, macrophage-specific GP-96 
deficient mice are relatively resistant to shock induced by systemic administration 
of LPS (TLR4 ligand), and macrophages isolated from these mice showed a 
significant decrease in cytokine production upon stimulation with multiple TLR 
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agonists, we aimed to investigate if the reduced TLR dependent responsiveness 
of GP-96 deficient macrophages would result in reduced inflammation and 
subsequently attenuated atherosclerosis in hyperlipidemic mice. The major finding 
in this study is that macrophage-specific GP-96 deficiency did not result in 
alteration in atherosclerosis in high fat diet-fed LDLR−/− mice, suggesting that GP-
96 does not play a significant role in macrophage inflammatory response in 
atherogenesis. 
GP-96 contributes to the correct functioning of TLR mediated responses. 
Myeloid GP-96 deficiency leads to loss of multiple TLRs including TLR1-9 except 
TLR3180. Increasing evidence suggests that TLRs are key orchestrators in 
atherosclerosis development. Activation of all TLRs except TLR3 triggers an 
intracellular signaling pathway mediated by myeloid differentiation primary-
response protein 88 (MyD88) or TIR domain-containing adaptor inducing IFN-β 
(TRIF), leading to the production of pro- and anti-inflammatory cytokines193. 
Previous evidence suggests that MyD88 plays a significant role in atherosclerosis. 
Deletion of the MyD88 gene in apoE−/− mice results in a significant reduction in 
aortic atherosclerosis and reduced macrophage accumulation194. However, bone 
marrow transplantation of MyD88 deficient DCs to LDLR−/− mice had 
atheroprotective effect195. The role of TLRs in atherosclerosis is still controversial; 
deficiency of TLRs in atherosclerosis mouse models showed conflicting effects on 
atherogenesis, e.g. TLR2/LDLR deficient mice developed less atherosclerosis 
compared to LDLR−/− mice. This result was confirmed in apoE −/− mice. However, 
no difference was observed in bone marrow transplantation studies, this finding 
  
102 
suggests that selective TLR2 cellular-type expression contributes differentially to 
lesion development196,197 . TLR1 and TLR6 did not affect atherosclerosis 
development in high fat diet-fed LDLR−/− mice198. Genetic deletion of TLR4 
dramatically reduced macrophage infiltration and atherosclerotic lesion 
development in apoE−/− mice187; whereas transplantation of TLR2/TLR4 deficient 
bone marrow cells to LDLR−/− mice fed a high fat diet did not result in changes in 
atherosclerosis198. Furthermore, TLR3 has been shown to be atheroprotective as 
the TLR3−/−/apoE−/− mice had more atherosclerosis than ApoE−/− mice189. Taken 
together, these studies showed conflicting outcomes of TLR manipulation 
depending on experimental conditions and models. Our study added another 
example of the complex role of TLRs in atherogenesis. 
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Table 4. 1 Primers that were used for qRT-PCR in this study 
 
Primers Forward (5’  3’) Reverse (5’  3’) 
18s CGCGGTTCTATTTTGTTGGT AGTCGGCATCGTTTATGGTC 
mGP-96 CATTTGAAATCAGTTCTCTCAG
GA 
AACGCATCACAGATAAGAGA
AC 
mTNF-α CGT CAGCCG ATTTGCTAT CT CGGACTCCGCAAAGTCTAAG 
mIL6 AGTTGCCTTCTTGGGACTGA TCCACGATTTCCCAGAGAAC 
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Figure 4. 1 In vivo experimental design, mouse model and bone marrow 
transplantation used for assessment of atherosclerosis  
Six to eight week-old female LDLR−/− mice were provided with antibiotics water 
containing neomycin (100 mg/L) and polymyxin B sulphate (60.000 U/L) one week 
before and two weeks after BMT. Mice received total body irradiation. Bone 
marrow cells were isolated from macrophage-specific GP-96 deficient mice or WT 
mice and 5 x 106 cells were injected into LDLR−/− mice in the retro-orbital plexus. 
Four weeks after the BMT, mice were fed a western diet for 9 weeks.  
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Figure 4. 2 Characterization of macrophage-specific GP-96 deficient mice 
Expression of the GP-96 isolated from peritoneal macrophages of macrophage-
specific GP-96 deficient mice and control (WT mice) (n = 3 per group) was 
examined by PCR (A) and western blot (B). Expression of GP-96 protein in 
macrophage, B cells and T cells isolated from spleen of macrophage-specific GP-
96 deficient mice and WT mice (C). Expression of TLR4 in peritoneal macrophages 
was assessed by western blot (n=3 per group). 
 
 
 
 
 
 
 
 
  
106 
 
 
 
Figure 4. 3 Effect of macrophage-specific GP-96 deficiency on mouse body 
weight, and food intake  
LDLR−/− mice were transplanted with bone marrow cells from macrophage-specific 
GP-96 deficient mice or control mice, allowed to recover for 4 weeks and 
subsequently fed a western diet for 9 weeks. Food intake (A) and body weight (B) 
were monitored weekly during the whole experiment.  
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Figure 4. 4 Effect of macrophage-specific GP-96 deficiency on inflammation 
(A) Spleen weight, (B) Flow cytometric analysis of splenocytes of LDLR−/− mice 
transplanted with bone marrow cells from macrophage-specific GP-96 deficient or 
WT mice and fed a western diet for 9 weeks. (C) Serum cytokine/chemokines were 
measured by Bio-Plex assays. 
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Figure 4. 5 Effect of macrophage-specific GP-96 deficiency on serum lipids 
After 9 weeks of western diet feeding, blood samples were drawn from retro-orbital 
puncture and the concentrations of cholesterol (A) and triglycerides (B) in the 
serum were determined. The distribution of cholesterol over the different 
lipoproteins was determined by FPLC. Cholesterol content in VLDL, LDL, and HDL 
fractions were measured (C). Fast blood glucose levels were determined (D). 
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Figure 4. 6 Effect of macrophage-specific GP-96 deficiency on 
atherosclerotic lesion development  
After 9 weeks of western diet, mice were sacrificed and their aortas and hearts 
were dissected. Aortas were cleaned, fixed in 10 % PFA, and stained with Sudan 
IV en face (A). Cross-sections throughout the aortic root area starting from the 
appearance of open aortic valve leaflets were used for atherosclerosis 
measurements. (B) Representative images and quantification of lesion area 
stained with H&E. (C) Representative images and quantification of lipid content in 
the aortic root as determined by ORO staining. (D) Representative images and 
quantification of aortic root macrophage infiltration as detected by immunostaining 
using MOMA-2 antibody. (E) Representative images and quantification of aortic 
root collagen content stained with trichrome.  
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Chapter V 
The therapeutic value of an anti-inflammatory Chinese herb compound, 
SsnB, for atherosclerosis 
5.1 Background 
Amounting clinical studies have shown that persistent low-grade 
inflammation is associated with the pathogenesis of chronic diseases such as 
atherosclerosis. Although high dose endotoxemia causes a significant increase in 
the inflammatory cytokines and acute tissue damage, low levels of circulating LPS 
have been implicated in initiating low-grade inflammation by mild and persistent 
increase in the expression of pro-inflammatory cytokines199. Low-grade 
endotoxemia may change the host immune environment into a mild non-resolving 
pro-inflammatory state, which eventually leads to slow and progressive tissue 
damage, leading to the pathogenesis and progression of chronic inflammatory 
diseases200. Recently, it has been shown that super-low dose LPS administration 
significantly promoted inflammation and exacerbated steatohepatitis in high fat 
diet-fed apoE−/− mice201.  
Sparstolonin B (SsnB) is a newly described, bioactive natural compound 
isolated and characterized from the Chinese herb Sparganium stoloniferum tubers 
which are used in Traditional Chinese Medicine (TCM) as a safe, non-toxic 
pharmaceutical agent for the treatment of several inflammatory diseases and as 
an anti-tumor agent. Our laboratory first isolated the compound and determined its 
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structure using NMR spectroscopy and X-ray crystallography. We showed that 
SsnB is a polyphenol with structural features of xanthone and isocoumarin , which 
has anti-oxidation and anti-inflammatory property202. We have previously shown: 
1) SsnB is a selective inhibitor of TLR2/TLR4 mediated inflammatory signaling via 
disruption of TIRAP/MyD88 interaction202; 2) SsnB attenuates inflammation and 
reduces production of inflammatory cytokines in macrophages and endothelial 
cells by selectively blocking TLR2/TLR4 signaling202,203; 3) SsnB significantly 
inhibited VSMCs proliferation, migration, inflammatory responses, and lipid 
accumulation in vitro204; 4) SsnB strongly attenuated cardiomyocyte inflammation 
in an ischemia/reperfusion injury model in vitro205; 5) SsnB inhibits pro-angiogenic 
functions and blocks cell cycle progression in human umbilical vein endothelial 
cells (HUVECs)206; and 6) SsnB is able to protect mice against endotoxin shock 
via inhibiting production of multiple cytokines and to attenuate hypoxia-induced 
apoptosis, necrosis, and inflammation in cultured rat left ventricular tissue slices207. 
All of these studies suggested that SsnB may act as a potential therapeutic agent 
for inflammatory diseases, such as atherosclerosis. Given the facts that 
macrophages and VSMCs play a significant role in atherosclerosis, and the anti-
inflammatory properties of SsnB on endothelial cells, VSMCs, and macrophages, 
we expected that SsnB could be a promising new agent for the prevention and 
treatment of inflammatory cardiovascular atherosclerotic diseases. In this study we 
tested the effect of SsnB on vascular inflammation and atherosclerosis 
development in an atherogenic mouse model after super-low dose LPS 
administration. We hypothesized that super-low dose LPS injection would promote 
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low grade chronic inflammation, and that SsnB may reduce the LPS induced 
inflammation and thereby attenuate atherosclerosis development.  
5.2 Material and Methods 
Mouse models 
Six to eight week-old female LDLR−/− mice on C57BL/6J background were 
purchased from the Jackson Laboratories (Bar Harbor, MA, USA) and maintained 
in pathogen-free conditions at the University of South Carolina Animal Research 
Facility according to National Institutes of Health (NIH) guidelines. All animal 
experiments were approved by the Institutional Animal Care and Use Committee 
(IACUC) at the University of South Carolina. Mice were placed on a western diet 
containing 21% (w/v) anhydrous milk-fat, 34% (w/v) sucrose, and a total of 0.2% 
(w/v) cholesterol (Harlan laboratories, Indianapolis, IN, USA) for 10 weeks. After 
two weeks of western diet, mice were randomly divided into 3 groups as follows: 
(1) LPS group, injected intraperitoneally (i.p.) with super-low dose LPS (4 ng/kg 
body weight, ~100 pg/mouse) dissolved in endotoxin free PBS; (2) SsnB group, 
injected i.p. with SsnB (4 mg/kg body weight) plus LPS (4 ng/kg body weight), and 
(3) PBS group, injected i.p. with the same volume of PBS (No LPS). Initially, mice 
were injected every other day for the first 4 weeks, then twice a week for another 
4 weeks. Body weight and food intake were monitored weekly. At the experimental 
endpoints, all mice were sacrificed; blood and serum were collected for analysis, 
aortas and aortic roots were harvested for atherosclerosis analysis. Liver samples 
were lysed in Triazol for qPCR. 
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VetScan hematology analysis  
Blood was collected from retro-orbital puncture into heparinized tubes. 
Blood samples were run on the VetScan HMT hematology analyzer (Abaxis, Union 
City, CA, USA). Different blood parameters were detected: total red blood cells 
(RBC), hemoglobin, mean corpuscular hemoglobin (MCH), mean corpuscular 
hemoglobin concentration (MCHC), hematocrit (Hct), platelet number, mean 
platelet volume (MPV), platelet distribution width (PDW), total white blood cells 
(WBC), lymphocytes, mean cell volume (MCV), and red cell distribution width 
(RDW).  
Serum lipid analysis  
Total serum cholesterol and triglyceride levels were measured using 
enzymatic colorimetric assays with Cholesterol Reagent and Triglycerides GPO 
reagent kits (Raichem; San Diego, CA, USA) and analyzed by SoftMax Pro5 
software (Molecular Devices, Sunnyvale CA, USA). Briefly, retro-orbital venous 
blood was collected. Serum was obtained via centrifugation at 4000 x g for 20 
minutes. Then, serum was diluted 1:100 in sterile water, 100 µL was loaded on the 
microplate well and 100 µL of freshly prepared cholesterol and triglyceride reagent 
were added to wells. The plates were incubated 10 minutes at 37⁰C and the 
absorbance was measured at 540 nm.  
Blood glucose measurement  
Blood glucose concentration was measured using OneTouch Ultra Blood 
Glucose Monitoring System (LifeScan, Inc., Milpitas, CA, USA) following the 
manufacturer’s instructions.  
  
115 
Bio-plex analysis of serum cytokine/chemokines 
Mouse serum levels of 23 cytokine/chemokines were measured using a Bio- 
Plex ProTM Mouse Cytokine 23-plex Assay (Bio-Rad, Hercules, CA, USA) on a Bio-
Plex system following the manufacturer’s instructions. 
Alanine Aminotransferase (ALT) measurement 
Liver function was assessed by measuring plasma alanine amino 
transferase (ALT) levels. At the experimental endpoint, blood was collected and 
serum isolated by centrifugation at 4000 x g for 20 minutes. ALT levels were 
measured using a Liquid ALT (SGPT) Reagent Set (Pointe Scientific, Inc. Canton, 
MI, USA) according to the manufacturer’s instructions. 
RNA extraction, cDNA synthesis, and quantitative real-time PCR 
Total mRNAs were extracted from liver tissue using Trizol reagent 
(Invitrogen) following the manufacturer’s instructions. One microgram of isolated 
mRNA was reverse transcribed into cDNA in 20 μL reactions using iScriptTM cDNA 
synthesis kit (Bio-Rad, Hercules, CA, USA). qRT-PCR was performed on a Bio-
Rad CFX96 system (Bio-Rad, Hercules, CA, USA) using iQ™ SYBR® Green 
Supermix (Bio-Rad, Hercules, CA, USA) according to the manufacturer’s 
instructions. The relative amount of target mRNA was calculated using the 2(-ΔΔCt) 
method by normalizing target mRNA Ct values to those of housekeeping gene, 
18S mRNA expression. PCR thermal cycling conditions were 3 minutes at 95°C, 
and 40 cycles of 15 s at 95°C and 58 s at 60°C. Samples were run in triplicate. 
Primers used are listed in table 5.1 
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Quantification of atherosclerosis  
At the experimental end point, mice were sacrificed. The aortas and aortic 
root were collected and processed as previously described in chapter 3 for 
atherosclerosis analysis. Aortas were stained with Sudan IV for aortic enface 
assay. Aortic root sections were stained with H&E, ORO, immunostaining using 
MOMA-2 antibody, and Masson’s trichrome to measure the atherosclerotic plaque 
area, lipid deposition, macrophage infiltration, and collagen percentage 
respectively. All images were recorded with a Nikon DS-Ri2 microscope and 
Micropublisher digital camera with Q-imaging software. Plaque size, lipid content, 
collagen percentage and macrophage cell content were quantified by 
computerized image Pro-Plus.  
Statistical analyses 
Data were presented as mean ± standard error of the mean (SEM). 
Statistical analysis was performed with GraphPad Prism 6.0 software (GraphPad 
Software Inc, San Diego, CA, USA). Statistical significance was determined by 
one-way analysis of variance (ANOVA) for multi-group comparison and Student’s 
t test for two-group comparison. Data were considered statistically significant at *P 
< 0.05, **P<0.01, and ***P<0.001. 
5.3 Results 
SsnB treatment and super-low dose LPS administration did not affect mouse 
food intake and body weight 
To induce atherosclerosis, LDLR−/− mice were fed a western diet for 10 
weeks to induce hyperlipidemia. After two weeks of western diet, mice were 
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divided into three groups. In the first group, mice were injected i.p. with super-low 
dose LPS (4 ng/kg body weight). While in the second group, mice were injected 
i.p. with SsnB (4 mg/kg body weight) along with LPS (4 ng/kg body weight), in the 
third group, mice were injected i.p. with 1 mL PBS. Food intake and body weight 
of the mice were monitored weekly. We did not observe significant differences in 
body weight and food intake between the groups over the course of the experiment 
(Figure 5.1A and 5.1B). 
SsnB treatment and super-low dose LPS administration did not affect blood 
cell profile 
To examine the effect of SsnB treatment after super-low dose LPS 
administration on blood cell profile, we performed a detailed hematological 
analysis. Vetscan HMT analysis indicated that there were no significant differences 
in all blood parameters including total white blood cells and white blood cell 
differential count, red blood cell number, hemoglobin concentration and 
hematocrit, Total blood platelet numbers and platelet hematocrit between the 
groups (Figures 5.2A, 5.2B, and 5.2C). 
SsnB treatment and super-low dose LPS administration did not affect serum 
lipid levels and blood glucose levels 
After 10 weeks of western diet and 8 weeks of super-low dose LPS and 
SsnB treatment, mice were fasted overnight, sacrificed, blood were collected and 
serum isolated as previously described. Serum total cholesterol and triglyceride 
levels were measured as well as fasting blood glucose levels. We did not observe 
any significant difference in the serum total cholesterol (Figure 5.3A), triglyceride 
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(Figure 5.3B), and fast blood glucose levels (Figure 5.3C) between PBS, LPS and 
SsnB groups. Indicating that superlow dose LPS administration and SsnB 
treatment did not affects lipid profile. 
SsnB treatment reduced serum chemokines induced by super-low dose LPS 
administration  
Chronic injection of subclinical super-low dose LPS has been shown to 
sustain a low grade inflammation in vitro and in vivo201,208. Furthermore, SsnB 
treatment dramatically reduced macrophage and endothelial cell inflammation in 
vitro202,203. We measured the spleen weight for these mice and found no difference 
between the groups (Figure 5.4A). We next detected the effects of super-low dose 
LPS and SsnB treatment on the inflammation in LDLR−/− mice fed a western diet 
by measuring several cytokine/chemokines levels in the serum using Bio-Plex 
assay. In agreement with a previous study201 several inflammatory biomarkers 
including keratinocyte-derived chemokine (KC), Macrophage inflammatory protein 
(MIP1-α and MIP1-β), and RANTES were increased by super-low dose LPS 
injection. Furthermore, SsnB treatment was able to significantly reduce the 
inflammatory chemokines p-value 0.0121, 0.0240, 0.0452 respectively (Figure 
5.4B). These chemokines are potent macrophage and lymphocyte 
chemoattractants and play a critical role in chronic inflammation. Macrophage 
inflammatory proteins (MIPs) are markedly up-regulated in macrophages upon 
exposure to bacterial LPS and increase their ability to recruit more inflammatory 
cells209. It has been shown that KC plays a central role in macrophage infiltration 
and accumulation in atherosclerotic lesions in mice210. In addition to that, some 
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other inflammatory cytokines such as IL3 and IL12(P40) were slighly increased 
after super-low dose LPS injection and SsnB slightly reduced these cytokines but 
without statistical significance. 
SsnB treatment has no impact on atherogenesis in LDLR−/− mice 
administered with super-low dose LPS and fed an atherogenic diet 
For atherosclerotic lesion analysis, the aorta and aortic root were isolated 
for atherosclerosis staining. In brief, the aortic roots were embedded in OCT for 
cryo-sectioning. Aortas were fixed in 10% neutral buffered formalin and stained 
with Sudan IV for the aortic enface analysis. The results showed that most of the 
lesions were localized specifically in the aortic sinus and aortic arch. The super-
low dose LPS injection as well as SsnB treatment did not significantly affect 
atherosclerotic lesion area of the aorta as and aortic root after 10 weeks of western 
diet (Figure 5.5A and 5.5B). Furthermore, the super-low dose LPS injection and 
SsnB treatment did not significantlly affect lipid deposion, lesional MOMA-2 
positive macrophage infiltration, and collagen deposition  in the aortic root lesions 
(Figure 5.5C, 5.5D, and 5.5E).   
Effects of SsnB treatment on liver function after super-low dose LPS 
administration  
Subclinical super-low dose LPS administration has been shown to initiate 
low grade-chronic inflammation and exacerbates liver inflammation as well as lipid 
accumulation201,208. We have shown previously that SsnB administrarion in 
experimental animal models attenuates early liver inflammation and injury in toxin-
induced steatohepatitis211. We therfore examined the effects of super-low dose 
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LPS injection and SsnB treatment on liver function in our experimental mouse 
model. At the experimental endpoint, we measured liver weight. Niether super-low 
dose LPS nor SsnB treatment changed the liver weight at the experimental 
endpoint (Figure 5.6A). Further, we collected serum from mice and examined the 
liver function by detecting serum ALT levels. As previously reported201, our results 
showed that super-low dose LPS administration slighly increased plasma ALT 
levels compared to the PBS group but without statistical significance. However, 
SsnB treatment did not affect ALT levels (Figure 5.6B). qRT-PCR was used to 
examine the expression levels of pro-inflammatory cytokines in the liver tissue. 
LDLR−/− mice injected with super-low dose LPS had a higher expression of 
inflammatory markers such as TNF-α and IL-6 compared to PBS group. Whereas, 
SsnB treatment slightly reduced the LPS induced IL6 expression and made no 
difference in TNF-α expression levels (Figure 5.6C and 5.6D). 
5.4 Discussion 
Atherosclerosis is a complex process involving many steps. Several lines 
of evidence ranging from animal experimental models to epidemiological studies 
support the notion that inflammation is one of the driving forces of 
atherogenesis22,62. However, the current treatments of atherosclerotic diseases 
are focused exclusively on reducing plasma lipid levels rather than reducing the 
harmful effects of acute and chronic inflammation. Recently, there has been 
intense interest in exploring specific anti-inflammation therapies to reduce the risk 
of cardiovascular diseases and offer an opportunity to directly test the inflammation 
hypothesis of atherosclerosis. Therefore, modulating systemic and local 
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inflammatory responses and targeting different inflammatory pathways might be 
effective in the treatment/prevention of atherosclerosis and may thereby reduce 
the risk of CVDs22,31,109.  
High dose LPS injection has been shown to significantly aggravate 
atherosclerosis via the activation of the nuclear factor kappa-B (NF-κB) pathway 
to secrete pro-inflammatory cytokines, including IL-6, MCP-1, and TNF-α212; but 
high dose LPS is not commonly observed in humans and thus not particularly 
clinically relevant. Subclinical super-low dose LPS is associated with persistent 
non-resolving chronic low-grade inflammation during the pathogenesis and 
progression of chronic diseases such as atherosclerosis and diabetes; and chronic 
exposure to low or very low dose of LPS is common and clinically relevant. Unlike 
high dose LPS, the super-low dose LPS does not activate NFκB pathway or induce 
the anti-inflammatory mediators213,214. Therefore, strategies targeting this low 
grade inflammation may demonstrate significant promise in not only the treatment, 
but also the reversal and prevention of chronic inflammatory diseases. 
A Chinese herb-derived compound, sparstolonin B (SsnB), selectively 
blocks TLR2/TLR4 mediated inflammatory signaling pathways such as MAPK and 
NF-κB pathways in macrophages202,215. SsnB has been shown to significantly 
reduce the expression of pro-inflammatory cytokines in high dose LPS-challenged 
mice202. However, the effect of SsnB on inflammation and atherosclerosis in 
atherogenic mice after super-low dose LPS administration has not been 
elucidated. In the present study, we found that super-low dose LPS and SsnB 
administration for 8 weeks did not affect mouse food intake and body weight after 
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10 weeks of western diet. In addition, blood cell profile and serum lipid levels did 
not change with SsnB treatment after super-low dose LPS administration. On the 
other hand, super-low dose LPS administration increased serum chemoattractant 
chemokines (RANTES, MIP1-α, and KC) and SsnB treatment attenuated the 
increase of these chemokines. Our study also showed that subclinical super-low 
dose LPS and SsnB treatment did not significantly alter lesion size in the aortic 
enface and aortic root lesions. Regarding plaque composition, no significant 
differences were observed in lipid deposition, macrophage infiltration and collagen 
content between groups. 
In conclusion, we show here that subclinical super-low dose LPS injection 
in LDLR−/− mice after 10 weeks of western diet did not significantly increased 
systemic inflammation and atherosclerotic lesion size at early stages as we 
expected. Furthermore, SsnB administration did not significantly affect plaque size 
or composition after super-low dose LPS injection. The effect of SsnB on 
atherosclerosis through suppressing TLR2/4 signaling warrants further 
investigations. 
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Table 5. 1 Primers that were used for qRT-PCR in this study 
 
Primers Forward (5’  3’) Reverse (5’  3’) 
m18S CGCGGTTCTATTTTGTTGGT AGTCGGCATCGTTTATGGTC 
mTNF-α CGTCAGCCG ATTTGCTATCT CGGACTCCGCAAAGTCTAAG 
mIL-6 AGTTGCCTTCTTGGGACTGA TCCACGATTTCCCAGAGAAC 
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Figure 5. 1 SsnB treatment and super-low dose LPS administration did not 
affect mouse food intake and body weight  
Six to eight week-old female LDLR−/− mice were fed a western diet for 10 weeks. 
During the last eight weeks, the mice were injected intraperitoneally with PBS, 
super-low dose LPS and SsnB. At the end of each indicated week mouse body 
weights (A) and food intake (B) were measured. The average daily intake of 
western diet per mouse during the week was calculated. 
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Figure 5. 2 SsnB treatment and super-low dose LPS administration did not 
affect blood cell profile  
Vetscan HMT blood cell analysis showed: (A) white blood leukocyte profile: total 
white blood cell number and white blood cell differential count (lymphocytes, 
monocytes, and neutrophils numbers and percentage). (B) Red blood cell (RBC) 
number, hemoglobin (HGB) concentration and hematocrit (HCT), as well as mean 
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean 
corpuscular hemoglobin concentration (MCHC), and red cell distribution width 
(RDWc) which is calculated as Standard deviation ÷ mean cell volume x 100. 
(C) Platelet related parameters of mice obtained by Vetscan HMT analysis. 
Parameters include total blood platelet count, mean platelet volume (MVP), platelet 
hematocrit (PCT), and platelet distribution width (PDWc) which is calculated using 
equation RDWc(%)  =  (Standard deviation ÷ mean cell volume) x 100. N = 7 mice 
each group. 
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Figure 5. 3 SsnB treatment and super-low dose LPS administration did not 
alter serum lipid and blood glucose levels  
Female LDLR−/− mice were fed a western diet for 10 weeks. During the last eight 
weeks, the mice were injected with LPS with or without SsnB every other day for 
the first four weeks then twice a week for another four weeks. At the experimental 
endpoint all mice were sacrificed and serum collected. Serum total cholesterol (A) 
and triglyceride (B). Fast blood glucose levels were determined (C).  
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Figure 5. 4 SsnB treatment reduced serum chemokines induced by super-
low dose LPS administration 
(A) Mouse spleen weight. (B) Serum levels of 23 cytokine/chemokines were 
measured by Bio-Plex Pro™ Mouse Cytokine 23-plex Assay. Data are presented 
as the mean ± SEM (n = 10 per group). *P < 0.05, **P < 0.01 
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Figure 5. 5 SsnB treatment has no impact on atherogenesis in LDLR−/− mice 
administered with super-low dose LPS and fed an atherogenic diet  
LDLR−/− mice were fed a western diet for 10 weeks to induce atherosclerosis. Mice 
were injected i.p. with super-low dose LPS (4 ng/kg body weight, ~100 pg/mouse) 
or LPS plus SsnB (4 mg/kg body weight) for 8 weeks. (A) Representative images 
and quantification of aortic enface stained with Sudan IV. (B) Representative 
images and quantification of lesion area in the aortic root frozen section of the 
control (PBS), LPS, and SsnB treatment mice stained with H&E. (C) 
Representative images and quantification of lipid content in the aortic root frozen 
section stained with ORO. (D) Representative images and quantification of 
macrophage infiltration in the aortic root frozen section stained with 
immunostaining using MOMA2 antibody. (E) Representative images and 
quantification of collagen content in the aortic root frozen section stained with 
trichrome staining. Data are presented as mean ± SEM. 
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Figure 5. 6 Effects of SsnB treatment on liver function after super-low dose 
LPS administration  
After sacrificing, mouse liver was thoroughly perfused to remove blood and then 
weighed. (A) Liver weight. (B) Serum ALT levels were determined at the end point. 
(d) Liver IL6, TNF-α gene expression were examined by qRT-PCR (*P < 0.05) 
  
133 
Chapter VI 
Summary and conclusion 
Atherosclerosis is a multi-stage and multifaceted disease. Both innate and 
adaptive immunity are involved in all phases of atherogenesis, from lesion initiation 
through progression and ultimately to the clinical complications of this disease50. 
All types of immune cells have been found in atherosclerotic lesions indicating that 
all immune components may participate in atherogenesis. Inflammation is a basic 
pathogenic element in the development and progression of atherosclerotic disease 
and in its manifestation. Inflammation is caused by complex interactions involving 
different cell types, different mediators, and different cellular processes. All of 
these factors form the basis of the “inflammation hypothesis of atherosclerosis”45. 
The relationship between inflammation and atherogenesis is complex. The link 
between inflammation and atherosclerosis provides a new avenue for future 
pharmacologic intervention that may slow the progression of atherosclerosis by 
targeting inflammation. Directly testing the inflammation hypothesis of 
atherosclerosis requires drugs that have systemic anti-inflammatory effect without 
affecting lipid levels. Experimental and clinical studies suggest that reducing 
inflammation without affecting lipid levels may reduce the rate of CVDs4,22,27,31. 
Recently, the phase III CANTOS study demonstrated that Canakinumab (IL1-β 
antibody) is the first and only drug that selectively targets inflammation and 
significantly reduces cardiovascular risk in patients with a prior heart attack and 
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inflammatory atherosclerosis84. IL1-β has been identified in early human 
atherosclerotic plaques and mouse models of atherosclerosis suggesting a causal 
role for IL-1β in atherogenesis. oxLDL, cholesterol crystals, and apoptotic cells 
have been identified as endogenous triggers of the NLRP3 inflammasome and 
secretion of IL-1β by plaque macrophages in atherosclerosis216. The expression of 
inflammation markers in atherosclerosis has been shown to be predictive of future 
cardiovascular risk. The detection of these inflammatory markers and immune 
profile may lead to a better stratification of asymptomatic patients. In particular, 
master cytokines such as IL-1β and IL-6 have been shown to independably predict 
the presence and the characteristics of the atherosclerotic plaque, whereas novel 
markers such as MMPs family including MMP-9 have been shown to be implicated 
in its destabilization. Inflammation markers may also provide a tool to follow 
atherosclerotic patients to assess their response to different therapies, and then 
allow for a better selection of appropriate strategy217,218.  
TTP is an anti-inflammatory protein that functions to promote mRNA 
decay219. The anti-inflammatory role of TTP has been extensively studied in mouse 
models and cell lines, such as blood monocytes and bone marrow–derived 
macrophages. The anti-inflammatory functions of TTP have been primarily studied 
in rheumatoid arthritis220. However, the role of TTP in atherosclerosis has not been 
examined. Our study shows that transplantation of TTP deficient bone marrow into 
atherogenic LDLR−/− mice resulted in dramatically increased systemic and multi-
organ inflammation. However, atherosclerotic lesion size and plaque composition 
were not significantly affected. Surprisingly, bone marrow TTP deficient mice 
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displayed a significant reduction in their plasma lipid and hepatic lipid 
accumulation, with reduced expression of SREBF-1 in the liver. It remains to be 
further determined how serum lipid and hepatic steatosis were severely reduced. 
Increased inflammation is counterbalanced by the reduction in serum lipid levels, 
resulting in no alteration in atherosclerosis development. This result reveals that 
targeting hematopoietic TTP activity may not be a suitable therapeutic approach. 
GP-96 is an essential chaperone for folding and function of multiple TLRs 
except TLR3. TLRs recognize pathogens and thereby initiate innate immune 
response. Deletion of GP-96 results in the post-translational loss of multiple TLRs, 
suggesting that this chaperone protein occupies a central position in the innate 
immunity. TLRs are implicated in the pathogenesis of atherosclerosis180,182,193. 
Targeting TLRs may provide alternative approaches and new therapy to halt 
atherosclerosis. However, evidence for the role of TLRs in atherosclerosis in 
mouse models is controversial. Some studies showed atheroprotective effects of 
TLRs, whereas others showed pro-atherogenic effects. This discrepancy can be 
partially explained by the use of different background strains of the mice221. 
Whether targeting TLRs is a successful approach for the treatment of 
atherosclerotic diseases remains to be determined. In this study we show that 
bone marrow transplantation of macrophage-specific GP-96 deficient cells into 
LDLR−/− mice did not result in any difference in inflammatory status, even though 
we confirmed the significant reduction in GP-96 and TLR4 expression in the 
peritoneal macrophages. Serum lipid levels were comparable between groups. 
Finally, these mice showed no difference in atherosclerotic lesion size and plaque 
  
136 
composition. Although more details regarding the TLRs function have recently 
been studied, the extent to which the different TLRs affect inflammation and 
immunity in atherosclerosis remains unclear. 
Traditional Chinese medicine (TCM), especially herbal medicine, has been 
used for the treatment of cardiovascular diseases for a very long time. Many 
compounds from these Chinese herbes are often capable of targeting multiple 
pathways. SsnB is a novel bioactive compound isolated and characterized in our 
lab; SsnB has anti-inflammatory properties by inhibiting TLR mediated 
signaling203,211,215. Inhibiting TLR2/TLR4 signaling pathway may be a fascinating 
therapeutic approach for atherosclerosis, however, no TLR2 or TLR4 antagonists 
have been approved for clinical use. SsnB has robust anti-inflammatory properties, 
but its effect on atherosclerosis is unknown. After super-low dose LPS injection, 
LDLR−/− mice showed a slight increase in inflammation and no change in serum 
lipid levels. Atherosclerotic lesions were comparable with the control mice. 
Furthermore, SsnB treatment had no effects on inflammation and atherosclerosis 
after super-low dose LPS injection. These results indicate that SsnB administration 
to western diet fed LDLR−/− mice is not effective to change inflammation and 
atherosclerosis development when the mice were injected with super-low dose 
LPS. The effect of SsnB on inflammation and atherosclerosis in atherogenic mice 
warrants further investigation using other animal models. 
In conclusion, our studies aimed to test the inflammation hypothesis of 
atherosclerosis using various models suggest that the role of inflammation in 
atherogenesis is complex. Some novel findings may guide us in future 
  
137 
investigations. First, we discovered a new role of miR155, a pro-inflammatory 
molecule, in promoting vascular calcification, suggesting that targeting vascular 
miR155 may be an effective preventive and therapeutic approach for 
cardiovascular diseases with vascular calcification as a pathological feature. 
Second, we discovered that systemic inflammation resulted from myeloid cell TTP 
deficiency surprisingly reduced plasma lipid levels and liver lipid accumulation, 
pointing to a possibility that a certain component of inflammation may actually 
benefit hepatic lipoprotein metabolism. Third, although TLR signaling has been 
implicated in the pathogenesis of atherosclerosis, direct targeting TLRs may not 
be an optimal approach for chronic diseases with low-level systemic inflammation, 
such as atherosclerosis.
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